

10/583,590

=> d his

(FILE 'HOME' ENTERED AT 15:53:15 ON 09 AUG 2011)

FILE 'REGISTRY' ENTERED AT 15:53:20 ON 09 AUG 2011

L1           STRUCTURE UPLOADED  
L2           50 S L1  
L3           4316 S L1 SSS FUL  
L4           STRUCTURE UPLOADED  
L5           3756 S L4 SUB=L3 FUL  
L6           560 S L3 NOT L5

FILE 'CAPLUS' ENTERED AT 16:08:23 ON 09 AUG 2011

L7           1 S US 20090143576/PN  
              SELECT RN L7 1-

FILE 'REGISTRY' ENTERED AT 16:08:44 ON 09 AUG 2011

L8           24 S E1-24  
L9           13 S L8 AND NRS=1  
L10          6 S L9 AND 6-7/SZ  
L11          7 S L9 NOT L10  
L12          46 S C11 H15 CL2 N . CL H/MF  
L13          1 S L11 AND L12

FILE 'CAPLUS' ENTERED AT 16:11:01 ON 09 AUG 2011

L14          1561 S L5  
L15          4 S L13  
L16          2 S L14 AND L15  
L17          17 S L6  
L18          4 S L15 OR L16

FILE 'REGISTRY' ENTERED AT 16:12:16 ON 09 AUG 2011

L19          491 S L6 AND CAPLUS/LC  
L20          69 S L6 NOT L19

FILE 'CAPLUS' ENTERED AT 16:12:51 ON 09 AUG 2011

=> d ibib abs hitstr total 117

L17 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2010:627117 CAPLUS

DOCUMENT NUMBER: 153:163337

TITLE: Thousands of chemical starting points for antimalarial lead identification

AUTHOR(S): Gamo, Francisco-Javier; Sanz, Laura M.; Vidal, Jaume; de Cozar, Cristina; Alvarez, Emilio; Lavandera, Jose-Luis; Vanderwall, Dana E.; Green, Darren V. S.; Kumar, Vinod; Hasan, Samiul; Brown, James R.; Peishoff, Catherine E.; Cardon, Lon R.; Garcia-Bustos, Jose F.

CORPORATE SOURCE: Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, 28760, Spain

SOURCE: Nature (London, United Kingdom) (2010), 465(7296), 305-310

CODEN: NATUAS; ISSN: 0028-0836

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Malaria is a devastating infection caused by protozoa of the genus Plasmodium. Drug resistance is widespread, no new chemical class of antimalarials has been introduced into clin. practice since 1996 and there is a recent rise of parasite strains with reduced sensitivity to the newest drugs. We screened nearly 2 million compds. in GlaxoSmithKline's chemical library for inhibitors of P. falciparum, of which 13,533 were confirmed to inhibit parasite growth by at least 80% at 2  $\mu$ M concentration. More than 8,000 also showed potent activity against the multidrug resistant strain Dd2. Most (82%) compds. originate from internal company projects and are new to the malaria community. Analyses using historic assay data suggest several novel mechanisms of antimalarial action, such as inhibition of protein kinases and host-pathogen interaction related targets. Chemical structures and associated data are hereby made public to encourage addnl. drug lead identification efforts and further research into this disease.

IT 583045-89-0

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antimalarial drugs lead identification)

RN 583045-89-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 44 THERE ARE 44 CAPLUS RECORDS THAT CITE THIS RECORD (44 CITINGS)

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN



ACCESSION NUMBER: 2010:82415 CAPLUS  
 DOCUMENT NUMBER: 152:168819  
 TITLE: Preparation of benzazepine derivatives for use as histamine H3 antagonists  
 INVENTOR(S): Pooni, Parminder Kaur; Merchant, Kevin John; Kerr, Catrina; Crosby, Stuart Richard; Okawa, Tomohiro; Sasaki, Mitsuru; Gotou, Mika; Showell, Graham Andrew; Teall, Martin Richard  
 PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited., Japan  
 SOURCE: PCT Int. Appl., 188pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.             | KIND  | DATE     | APPLICATION NO.  | DATE       |
|------------------------|---|----------|------------------|------------|
| WO 2010007382          | A1  | 20100121 | WO 2009-GB1774   | 20090717   |
| W:                     | AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW, |          |                  |            |
| RW:                    | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  |          |                  |            |
| AU 2009272486          | A1  | 20100121 | AU 2009-272486   | 20090717   |
| CA 2731196             | A1  | 20100121 | CA 2009-2731196  | 20090717   |
| KR 2011036044          | A   | 20110406 | KR 2011-7001319  | 20090717   |
| EP 2326625             | A1  | 20110601 | EP 2009-784728   | 20090717   |
| R:                     | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, AL, BA, RS  |          |                  |            |
| CN 102099339           | A   | 20110615 | CN 2009-80127932 | 20090717   |
| US 20110124626         | A1  | 20110526 | US 2011-54688    | 20110118   |
| PRIORITY APPLN. INFO.: |   |          | GB 2008-13254    | A 20080718 |
|                        |   |          | GB 2009-5231     | A 20090326 |
|                        |   |          | WO 2009-GB1774   | W 20090717 |


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 152:168819; MARPAT 152:168819

GI




- AB Title compds. I [A = OC(O), C(O)O, CO, cycloalkylene, etc.; X = absent, (un)substituted alkylene, or alkenylene; Z = (un)substituted aryl, heteroaryl, cycloalkyl, or heterocyclyl; R1 = (un)substituted cycloalkyl, alkyl, alkylene-cycloalkyl, or heterocyclyl; n = 0 to 4; with provisions], and their pharmaceutically acceptable salts, are prepared and disclosed as histamine H3 antagonists. Thus, e.g., II was prepared by reductive amidation of 7-Bromo-2,3,4,5-tetrahydro-1H-benzo[d]azepine with cyclobutanone followed by addition to tert-Bu 1-oxa-6-azaspiro[2.5]octane-6-carboxylate, deprotection, and amidation with propionyl chloride. Select I were evaluated in H3 binding assays (data given).
- IT 1204828-87-4P 1204828-88-5P 1204828-89-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of benzazepine derivs. for use as histamine H3 antagonists)
- RN 1204828-87-4 CAPLUS
- CN 3H-3-Benzazepine-3-carboxylic acid,  
 1,2,4,5-tetrahydro-7-[(phenylsulfonyl)methyl]-, 1,1-dimethylethyl ester  
 (CA INDEX NAME)




- RN 1204828-88-5 CAPLUS
- CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[(phenylsulfonyl)methyl]-,  
 hydrochloride (1:1) (CA INDEX NAME)

10/583,590



● HCl

RN 1204828-89-6 CAPLUS  
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-  
[(phenylsulfonyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD  
(4 CITINGS)  
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2009:1316120 CAPLUS

DOCUMENT NUMBER: 152:66477

TITLE: The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor

AUTHOR(S): Bailey, James M.; Scott, Jackie S.; Basilla, Jonathan B.; Bolton, Victoria J.; Boyfield, Izzy; Evans, David G.; Fleury, Etienne; Heightman, Tom D.; Jarvie, Emma M.; Lawless, Kirk; Matthews, Kim L.; McKay, Fiona; Mok, Hindy; Muir, Alison; Orlek, Barry S.; Sanger, Gareth J.; Stemp, Geoffrey; Stevens, Alexander J.; Thompson, Mervyn; Ward, John; Vaidya, Kalindi; Westaway, Susan M.

CORPORATE SOURCE: Immuno-Inflammation Centre of Excellence for Drug Discovery, Medicines Research Centre, GlaxoSmithKline, Stevenage, Herts, SG1 2NY, UK

SOURCE: Bioorganic &amp; Medicinal

Chemistry Letters (2009), 19(22), 6452-6458  
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 152:66477


AB Optimization of a series of benzazepine sulfonamide hit compds. identified from high throughput screening led to the discovery of a new series of tractable, potent motilin receptor agonists.

|    |              |              |              |
|----|--------------|--------------|--------------|
| IT | 789487-55-4  | 1201677-67-9 | 1201677-68-0 |
|    | 1201677-69-1 | 1201677-71-5 | 1201677-72-6 |
|    | 1201677-73-7 | 1201677-74-8 | 1201677-75-9 |
|    | 1201677-76-0 | 1201677-77-1 | 1201677-78-2 |
|    | 1201677-79-3 | 1201677-82-8 | 1201677-83-9 |
|    | 1201677-85-1 | 1201677-86-2 | 1201677-87-3 |
|    | 1201677-88-4 | 1201678-02-5 | 1201678-03-6 |
|    | 1201678-04-7 | 1201678-05-8 | 1201678-06-9 |
|    | 1201678-09-2 |              |              |

RL: PAC (Pharmacological activity); BIOL (Biological study)  
(discovery and optimization of benzazepine sulfonamide and sulfones as potent agonists of motilin receptor)


RN 789487-55-4 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 1201677-67-9 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 1201677-68-0 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-[(tetrahydro-3-furanyl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-69-1 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(1-methyl-4-piperidinyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 1201677-71-5 CAPLUS


CN Benzenesulfonamide, N-[3-(1-acetyl-4-piperidinyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-butyl- (CA INDEX NAME)



RN 1201677-72-6 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 1201677-73-7 CAPLUS

CN Acetamide, N-[3-[[7-[[4-(4-butylphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]phenyl]- (CA INDEX NAME)




RN 1201677-74-8 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(2-thienylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 1201677-75-9 CAPLUS


CN Acetamide, N-[5-[[7-[[4-(4-butylphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]methyl]-2-thienyl]- (CA INDEX NAME)



RN 1201677-76-0 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(1H-imidazol-5-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)






RN 1201677-77-1 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-[(4-methyl-1H-imidazol-5-yl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-78-2 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-[(2-methyl-1H-imidazol-5-yl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-79-3 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-[(1-methyl-1H-imidazol-5-yl)methyl]-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-82-8 CAPLUS

CN Benzenemethanesulfonamide, N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-83-9 CAPLUS

CN Benzenesulfonamide, 4-cyano-N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201677-85-1 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 1201677-86-2 CAPLUS


CN Benzenesulfonamide, 3-chloro-4-methyl-N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 1201677-87-3 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 1201677-88-4 CAPLUS

CN Benzenesulfonamide, 4-(1-methylethoxy)-N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 1201678-02-5 CAPLUS

CN 1H-3-Benzazepine, 7-[[4-(4-butylphenyl)sulfonyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 1201678-03-6 CAPLUS


CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[(phenylsulfonyl)methyl]- (CA INDEX NAME)




RN 1201678-04-7 CAPLUS

CN 1H-3-Benzazepine, 7-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)


10/583,590




RN 1201678-05-8 CAPLUS  
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[(2-naphthalenylsulfonyl)methyl]-  
(CA INDEX NAME)



RN 1201678-06-9 CAPLUS  
CN 1H-3-Benzazepine, 7-[[ (4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-  
2,3,4,5-tetrahydro- (CA INDEX NAME)




RN 1201678-09-2 CAPLUS  
CN 1H-3-Benzazepine, 7-[[ (3',4'-difluoro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-  
2,3,4,5-tetrahydro- (CA INDEX NAME)




IT 1201677-80-6  
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)  
(discovery and optimization of benzazepine sulfonamide and sulfones as potent agonists of motilin receptor)  
RN 1201677-80-6 CAPLUS  
CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(1H-pyrazol-3-ylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)


10/583,590



IT 1201678-07-0P  
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(discovery and optimization of benzazepine sulfonamide and sulfones as potent agonists of motilin receptor)  
RN 1201678-07-0 CAPLUS  
CN 1H-3-Benzazepine, 7-[[[(4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-2,3,4,5-tetrahydro- (CA INDEX NAME)




IT 583025-17-6P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
(discovery and optimization of benzazepine sulfonamide and sulfones as potent agonists of motilin receptor)  
RN 583025-17-6 CAPLUS  
CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




IT 956102-17-3P 1201678-21-8P 1201678-24-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(discovery and optimization of benzazepine sulfonamide and sulfones as potent agonists of motilin receptor)  
RN 956102-17-3 CAPLUS  
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[[(4-butylphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)


10/583,590



RN 1201678-21-8 CAPLUS  
CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[4-(n-butyl)sulfonyl]methyl]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl  
ester (CA INDEX NAME)




RN 1201678-24-1 CAPLUS  
CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[4'-fluoro[1,1'-biphenyl]-4-yl]sulfonyl]methyl]-1,2,4,5-tetrahydro-,  
1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)  
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L17 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN  
 ACCESSION NUMBER: 2009:322791 CAPLUS  
 DOCUMENT NUMBER: 150:554899  
 TITLE: 7-Sulfonamido-3-benzazepines as potent and selective  
 5-HT<sub>2C</sub> receptor agonists: Hit-to-lead optimization  
 AUTHOR(S): Fish, Paul V.; Brown, Alan D.; Evrard, Edel; Roberts,  
 Lee R.  
 CORPORATE SOURCE: Discovery Chemistry, Sandwich Laboratories, Pfizer  
 Global Research and Development, Sandwich, Kent, CT13  
 9NJ, UK  
 SOURCE: Bioorganic & Medicinal  
 Chemistry Letters (2009),  
 19(7), 1871-1875  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 150:554899  
 GI



AB New 7-sulfonamido-3-benzazepines (I) are disclosed as 5-HT<sub>2C</sub> receptor agonists. Appropriate substitution of the amino group (R<sub>1</sub>R<sub>2</sub>N-) gave compds. that were potent 5-HT<sub>2C</sub> agonists with minimal activation of the 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors. Furthermore, representative examples had excellent in vitro ADME properties and good selectivity over ion channel activity.

IT 1154438-36-4P 1154438-38-6P 1154438-40-0P  
 1154438-47-7P 1154438-95-5P 1154438-97-7P  
 1154438-99-9P 1154439-01-6P  
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (7-sulfonamido-3-benzazepines as potent and selective 5-HT<sub>2C</sub> receptor agonists in hit-to-lead optimization program)


RN 1154438-36-4 CAPLUS  
 CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-phenyl- (CA INDEX NAME)



10/583,590


RN 1154438-38-6 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, N-(2-fluorophenyl)-2,3,4,5-tetrahydro-  
(CA INDEX NAME)




RN 1154438-40-0 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, N-(2-chlorophenyl)-2,3,4,5-tetrahydro-  
(CA INDEX NAME)




RN 1154438-47-7 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-methyl-N-phenyl- (CA  
INDEX NAME)



RN 1154438-95-5 CAPLUS

CN Benzenesulfonamide, 2-fluoro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-  
(CA INDEX NAME)




RN 1154438-97-7 CAPLUS

CN Benzenesulfonamide, 2-fluoro-N-methyl-N-(2,3,4,5-tetrahydro-1H-3-  
benzazepin-7-yl)- (CA INDEX NAME)




10/583,590




RN 1154438-99-9 CAPLUS

CN Benzenemethanesulfonamide, 4-fluoro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 1154439-01-6 CAPLUS

CN Benzenemethanesulfonamide, 4-fluoro-N-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:1249178 CAPLUS

DOCUMENT NUMBER: 150:252

TITLE: Tricyclic azepine derivatives as selective brain penetrant 5-HT<sub>6</sub> receptor antagonists

AUTHOR(S): Trani, Giancarlo; Baddeley, Stuart M.; Briggs, Michael A.; Chuang, Tsu T.; Deeks, Nigel J.; Johnson, Christopher N.; Khazragi, Abir A.; Mead, Tania L.; Medhurst, Andrew D.; Milner, Peter H.; Quinn, Leann P.; Ray, Alison M.; Rivers, Dean A.; Stean, Tania O.; Stemp, Geoffrey; Trail, Brenda K.; Witty, David R.

CORPORATE SOURCE: Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK

SOURCE: Bioorganic &amp; Medicinal

Chemistry Letters (2008),

18(20), 5698-5700

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Starting from a benzazepine sulfonamide 5-HT<sub>6</sub> receptor antagonist lead with limited brain penetration, application of a strategy of conformational constraint and reduction of hydrogen bond donor count led to a novel series of tricyclic derivs. with high 5-HT<sub>6</sub> receptor affinity and excellent brain:blood ratios.


IT 1087197-72-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(tricyclic azepine derivs. as selective brain penetrant 5-HT<sub>6</sub> receptor antagonists)

RN 1087197-72-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
1,2,4,5-tetrahydro-7-[(phenylsulfonyl)amino]-8-[2-(trimethylsilyl)ethynyl]-  
, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 585570-84-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tricyclic azepine derivs. as selective brain penetrant 5-HT<sub>6</sub> receptor antagonists)

RN 585570-84-9 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590



|                      |    |   |
|----------------------|----|---|
| OS.CITING REF COUNT: | 7  | THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)                                      |
| REFERENCE COUNT:     | 10 | THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT |

L17 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:881207 CAPLUS  
 DOCUMENT NUMBER: 149:168025  
 TITLE: Use of 5-HT6 antagonists to prevent relapse into addiction  
 INVENTOR(S): De Bruin, Natasja M. W. J.; Van Loevezijn, Arnold; Wijnen, Johan; Herremans, Arnoldus H. J.; Kruse, Cornelis G.  
 PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.  
 SOURCE: PCT Int. Appl., 28pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2008087123          | A2   | 20080724 | WO 2008-EP50360 | 20080115   |
| WO 2008087123          | A3   | 20081127 |                 |            |
| W:                     | AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW |          |                 |            |
| RW:                    | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA   |          |                 |            |
| AR 64860               | A1   | 20090429 | AR 2008-100125  | 20080111   |
| PRIORITY APPLN. INFO.: |  |          | EP 2007-100576  | A 20070116 |
|                        |  |          | US 2007-880421P | P 20070116 |

OTHER SOURCE(S): MARPAT 149:168025


AB The invention discloses the use of compds., and pharmaceutically acceptable salts thereof, which are 5-HT6 antagonists. These compds. are useful for the preparation of medicaments for preventing relapse into addiction, in particular relapse into addiction to substances of abuse, including opiates, hallucinogens, inhalants, phencyclidine, amphetamines, cocaine, cannabis, nicotine, and alc., into relapse to addiction to certain medicines, including sedatives, hypnotics and anxiolytics, and into relapse to certain addictive behaviors, including gambling.

IT 583045-76-5, SB 737050A 583045-76-5D, SB 737050A, stereoisomers, tautomers, N-oxides, isotopically labeled analogs, or salts  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (5-HT6 antagonists for prevention of relapse into addiction)

RN 583045-76-5 CAPLUS


CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590



RN 583045-76-5 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L17 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:858203 CAPLUS

DOCUMENT NUMBER: 149:144007

TITLE: Use of 5-HT6 antagonists to prevent relapse into addiction

INVENTOR(S): De Bruin, Natasja M. W. J.; Van Loevezijn, Arnold; Wijnen, Johan; Herremans, Arnoldus H. J.; Kruse, Cornelis G.

PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.

SOURCE: U.S. Pat. Appl. Publ., 15pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO.             | KIND | DATE     | APPLICATION NO. | DATE       |
|------------------------|------|----------|-----------------|------------|
| -----                  | ---- | -----    | -----           | -----      |
| US 20080171779         | A1   | 20080717 | US 2008-13898   | 20080114   |
| PRIORITY APPLN. INFO.: |      |          | US 2007-880421P | P 20070116 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 149:144007


AB The invention discloses the use of compds., and pharmaceutically acceptable salts thereof, which are 5-HT6 antagonists. In one embodiment, the invention relates to the use of these compds., or pharmaceutical compns. comprising these compds., for preventing relapse into addiction, e.g. relapse into addiction to substances of abuse, including opiates, hallucinogens, inhalants, phencyclidine, amphetamines, cocaine, cannabis, nicotine, and alc., relapse into addiction to certain medicines, including sedatives, hypnotics and anxiolytics, and relapse into certain addictive behaviors, including gambling.

IT 583045-76-5, SB 737050A 583045-76-5D, tautomers, stereoisomers, N-oxides, salts, and isotopically labeled analogs  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(5-HT6 antagonists to prevent relapse into addiction)

RN 583045-76-5 CAPLUS


CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-76-5 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L17 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:411959 CAPLUS

DOCUMENT NUMBER: 148:403094

TITLE: Preparation of benzazepine carboxamides as ion channel modulators useful in the prophylaxis and treatment of inflammatory and immunological diseases

INVENTOR(S): Lawton, Geoff; Kozlowski, Roland; Hogg, Dayle

PATENT ASSIGNEE(S): Lectus Therapeutics Limited, UK

SOURCE: PCT Int. Appl., 69pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2008038051          | A2   | 20080403 | WO 2007-GB50591 | 20070928   |
| WO 2008038051          | A3   | 20080619 |                 |            |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW |          |                 |            |
| RW:                    | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA   |          |                 |            |
| WO 2008038053          | A1   | 20080403 | WO 2007-GB50593 | 20070928   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW |          |                 |            |
| RW:                    | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM   |          |                 |            |
| EP 2066317             | A2   | 20090610 | EP 2007-804494  | 20070928   |
| R:                     | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS   |          |                 |            |
| EP 2069309             | A1   | 20090617 | EP 2007-804496  | 20070928   |
| R:                     | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS   |          |                 |            |
| JP 2010504953          | T  | 20100218 | JP 2009-529780  | 20070928   |
| JP 2010504954          | T  | 20100218 | JP 2009-529781  | 20070928   |
| US 20110130383         | A1   | 20110602 | US 2009-443396  | 20090327   |
| US 20090318423         | A1   | 20091224 | US 2009-443402  | 20090414   |
| PRIORITY APPLN. INFO.: |  |          | GB 2006-19176   | A 20060929 |





WO 2007-GB50591 W 20070928

WO 2007-GB50593 W 20070928

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 148:403094; MARPAT 148:403094

GI



AB The title compds. I [A and B = CH<sub>2</sub> or CH<sub>2</sub>CH<sub>2</sub>; R<sub>1</sub> = H, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl; R<sub>2</sub>-R<sub>4</sub> = H, alkyl, halo, haloalkyl, alkoxy, alkoxy carbonyl, carboxyl, hydroxyl or cyano; X = R<sub>5</sub>CO, R<sub>5</sub>SO<sub>2</sub>, R<sub>5</sub>R<sub>7</sub>NCO, R<sub>5</sub>R<sub>7</sub>NSO<sub>2</sub>, R<sub>5</sub>SO<sub>2</sub>NR<sub>7</sub>CO or CO<sub>2</sub>R<sub>8</sub>; Y = R<sub>6</sub>CO, R<sub>6</sub>SO<sub>2</sub>, R<sub>6</sub>R<sub>7</sub>NCO, R<sub>6</sub>R<sub>7</sub>NSO<sub>2</sub>, R<sub>6</sub>SO<sub>2</sub>NR<sub>7</sub>CO or CO<sub>2</sub>R<sub>8</sub>; R<sub>5</sub> and R<sub>6</sub> = H, alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; R<sub>7</sub> = H, alkyl, aryl or aralkyl; R<sub>8</sub> = alkyl, aryl, aralkyl, alkoxyalkyl, heteroaryl or heteroarylalkyl; provided that when X is R<sub>5</sub>CO or R<sub>5</sub>SO<sub>2</sub>, then Y is not R<sub>6</sub>CO, R<sub>6</sub>SO<sub>2</sub> or R<sub>6</sub>R<sub>7</sub>NCO], useful in the manufacture of a medicament for the prophylaxis or treatment of inflammatory or immunol. disease (alone or in combination with other therapeutic agents), were prepared. Thus, treating 7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine with trimethylsilyl isocyanate in CHCl<sub>3</sub> followed by the addition of p-toluenesulfonyl isocyanate afforded II as triethylamine salt.

IT 1016265-22-7P 1016265-57-8P 1016265-59-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzazepine carboxamides as ion channel modulators useful in the prophylaxis and treatment of inflammatory and immunol. diseases)

RN 1016265-22-7 CAPLUS


CN 3H-3-Benzazepine-3-carboxamide, 1,2,4,5-tetrahydro-N-[(4-methylphenyl)sulfonyl]-7-[(phenylsulfonyl)amino]- (CA INDEX NAME)

10/583,590




RN 1016265-57-8 CAPLUS

CN 3H-3-Benzazepine-3-carboxamide, 1,2,4,5-tetrahydro-N-[(4-methylphenyl)sulfonyl]-7-[[4-methylphenyl)sulfonyl]amino]- (CA INDEX NAME)



RN 1016265-59-0 CAPLUS

CN 3H-3-Benzazepine-3-carboxamide, 7-[[[1,1'-biphenyl]-4-ylsulfonyl]amino]-1,2,4,5-tetrahydro-N-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)




IT 585570-84-9P 585570-87-2P 1016265-95-4P  
1016266-36-6P 1016266-39-9P 1016266-41-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzazepine carboxamides as ion channel modulators useful in the prophylaxis and treatment of inflammatory and immunol. diseases)

RN 585570-84-9 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/583,590


RN 585570-87-2 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-  
(CA INDEX NAME)




RN 1016265-95-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
1,2,4,5-tetrahydro-7-[(phenylsulfonyl)amino]-, phenylmethyl ester (CA  
INDEX NAME)



RN 1016266-36-6 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,  
1,2,4,5-tetrahydro-7-[[ (4-methylphenyl)sulfonyl]amino]-, phenylmethyl  
ester (CA INDEX NAME)



RN 1016266-39-9 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[([1,1'-biphenyl]-4-ylsulfonyl)amino]-1,2,4,5-tetrahydro-, phenylmethyl  
ester (CA INDEX NAME)

10/583,590



RN 1016266-41-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-  
(CA INDEX NAME)



OS.CITING REF COUNT: 1

THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L17 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2007:1469363 CAPLUS

DOCUMENT NUMBER: 148:93272

TITLE: Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity, and therapeutic use

INVENTOR(S): Codony-Soler, Xavier; Buschmann, Helmut Henrich

PATENT ASSIGNEE(S): Laboratorios Del Dr. Esteve, S.A., Spain

SOURCE: PCT Int. Appl., 254 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO.  | DATE       |
|------------------------|--|----------|------------------|------------|
| WO 2007147883          | A1   | 20071227 | WO 2007-EP56234  | 20070622   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW |          |                  |            |
| RW:                    | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM   |          |                  |            |
| CA 2658959             | A1   | 20071227 | CA 2007-2658959  | 20070622   |
| EP 2040755             | A1   | 20090401 | EP 2007-765553   | 20070622   |
| EP 2040755             | B1   | 20110518 |                  |            |
| R:                     | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS   |          |                  |            |
| JP 2009541423          | T  | 20091126 | JP 2009-517134   | 20070622   |
| AT 509636              | T  | 20110615 | AT 2007-765553   | 20070622   |
| IN 2008KN05064         | A  | 20090327 | IN 2008-KN5064   | 20081212   |
| MX 2008015996          | A  | 20090120 | MX 2008-15996    | 20081215   |
| CN 101500611           | A  | 20090805 | CN 2007-80025116 | 20081231   |
| US 20100120747         | A1   | 20100513 | US 2009-305516   | 20090326   |
| PRIORITY APPLN. INFO.: |  |          | EP 2006-384012   | A 20060623 |
|                        |  |          | WO 2007-EP56234  | W 20070622 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 148:93272

AB The invention discloses a combination comprising at least one compound with 5-HT6 receptor affinity, and at least one cholinesterase inhibitor, as well as a medicament comprising the combination, and the use of the combination for the manufacture of a medicament.

IT 585570-88-3 585570-88-3D, enantiomers and salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)


(cholinesterase inhibitor combination with compound with 5-HT6 receptor affinity)

RN 585570-88-3 CAPLUS

CN Benzenesulfonamide, 2,3-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-


10/583,590

y1)- (CA INDEX NAME)



RN 585570-88-3 CAPLUS

CN Benzenesulfonamide, 2,3-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3

THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2007:1356517 CAPLUS

DOCUMENT NUMBER: 148:92237

TITLE: New Serotonin 5-HT<sub>6</sub> Ligands from Common Feature Pharmacophore Hypotheses

AUTHOR(S): Kim, Hye-Jung; Doddareddy, Munikumar Reddy; Choo, Hyunah; Cho, Yong Seo; No, Kyoung Tai; Park, Woo-Kyu; Pae, Ae Nim

CORPORATE SOURCE: Life Science Division, Korea Institute of Science and Technology, Seoul, 130-650, S. Korea

SOURCE: Journal of Chemical Information and Modeling (2008), 48(1), 197-206

CODEN: JCISD8; ISSN: 1549-9596

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Serotonin 5-HT<sub>6</sub> receptor antagonists are thought to play an important role in the treatment of psychiatry, Alzheimer's disease, and probably obesity. To find novel and potent 5-HT<sub>6</sub> antagonists and to provide a new idea for drug design, we used a ligand-based pharmacophore to perform the virtual screening of a com. available database. A three-dimensional common feature pharmacophore model was developed by using the HipHop program provided in Catalyst software and was used as a query for screening the database. A recursive partitioning (RP) model which can sep. active and inactive compds. was used as a filtering system. Finally a sequential virtual screening procedure (SQSP) was conducted, wherein both the common feature pharmacophore and the RP model were used in succession to improve the results. Some of the hits were selected based on druglikeness, ADME properties, structural diversity, and synthetic accessibility for real biol. evaluation. The best hit compound showed a significant IC<sub>50</sub> value of 9.6 nM and can be used as a lead for further drug development.


IT 585570-88-3

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(drug design, structure-activity profile and a sequential virtual screening procedure for new serotonin 5-HT<sub>6</sub> ligands from common feature pharmacophore hypotheses)

RN 585570-88-3 CAPLUS

CN Benzenesulfonamide, 2,3-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2007:79574 CAPLUS

DOCUMENT NUMBER: 146:197771

TITLE: Studies towards the identification of a new generation of atypical antipsychotic agents

AUTHOR(S): Garzya, Vincenzo; Forbes, Ian T.; Gribble, Andrew D.; Hadley, Mike S.; Lightfoot, Andrew P.; Payne, Andrew H.; Smith, Alexander B.; Douglas, Sara E.; Cooper, David G.; Stansfield, Ian G.; Meeson, Malcom; Dodds, Emma E.; Jones, Declan N. C.; Wood, Martyn; Reavill, Charlie; Scorer, Carol A.; Worby, Angela; Riley, Graham; Eddershaw, Peter; Ioannou, Chris; Donati, Daniele; Hagan, Jim J.; Ratti, Emiliangelo A.

CORPORATE SOURCE: New Frontiers Science Park, Psychiatry Centre of Excellence for Drug Discovery, Essex, CM19 5AW, UK

SOURCE: Bioorganic &amp; Medicinal

Chemistry Letters (2007), 17(2), 400-405

CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:197771

GI



I

AB A lead optimization program led to the identification of sulfonamide I (25), a mol. combining dopamine D<sub>2</sub>/D<sub>3</sub> receptor antagonism with serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>6</sub> receptor antagonism for an effective treatment of schizophrenia. Compound I was shown to possess the required in vivo activity with no EPS liability.


IT 583025-17-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(heterocyclic sulfonamides as dopamine and serotonin receptor antagonists)

RN 583025-17-6 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-  
(CA INDEX NAME)






IT 583025-18-7P 583044-70-6P 583044-97-7P  
 583045-11-8P 583045-89-0P 583046-87-1P  
 583047-05-6P 753447-17-5P 923573-88-0P  
 923573-89-1P 923573-90-4P 923573-91-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(heterocyclic sulfonamides as dopamine and serotonin receptor antagonists)


RN 583025-18-7 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-70-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-97-7 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/583,590


RN 583045-11-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-89-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-87-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583047-05-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 753447-17-5 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 923573-88-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3'-chloro-4'-fluoro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 923573-89-1 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-2-thienyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 923573-90-4 CAPLUS

CN Benzenesulfonamide, 4-(3,5-dimethyl-4-isoxazolyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 923573-91-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




IT 583044-69-3P 583044-96-6P 583045-88-9P  
 583047-45-4P 732982-31-9P 755750-84-6P  
 783302-10-3P 956102-17-3P 956103-24-5P  
 956115-77-8P 956115-81-4P 956116-16-8P  
 956116-94-2P 956126-02-6P 956126-06-0P  
 956126-17-3P 956126-23-1P 956126-84-4P  
 956127-01-8P 956127-02-9P 956127-28-9P  
 956140-80-0P 956141-98-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(heterocyclic sulfonamides as dopamine and serotonin receptor antagonists)


RN 583044-69-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-96-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-88-9 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 583047-45-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-8-(dimethylamino)-  
1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 732982-31-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-  
1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 755750-84-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[8-(dimethylamino)-2,3,4,5-  
tetrahydro-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 783302-10-3 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-(2,3,4,5-tetrahydro-1H-  
3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 956102-17-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[ (4-butylphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl  
ester (CA INDEX NAME)




RN 956103-24-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[ (4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-1,2,4,5-tetrahydro-,  
1,1-dimethylethyl ester (CA INDEX NAME)




RN 956115-77-8 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[ (3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-1,2,4,5-  
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 956115-81-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3'-chloro-4'-fluoro-N-(2,3,4,5-tetrahydro-  
1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 956116-16-8 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4'-(2-chloro-3-fluorophenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-  
1,1-dimethylethyl ester (CA INDEX NAME)




RN 956116-94-2 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4'-(4-chloro-2-methylphenyl)sulfonyl]amino]-1,2,4,5-  
tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 956126-02-6 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,  
1,2,4,5-tetrahydro-7-[[[4-(5-methyl-2-thienyl)phenyl]sulfonyl]amino]-,  
1,1-dimethylethyl ester (CA INDEX NAME)



10/583,590


RN 956126-06-0 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-2-thienyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 956126-17-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[[4-(3,5-dimethyl-4-isoxazolyl)phenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 956126-23-1 CAPLUS

CN Benzenesulfonamide, 4-(3,5-dimethyl-4-isoxazolyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 956126-84-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[[4'-(4-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-1,2,4,5-tetrahydro-8-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)






10/583,590




RN 956127-01-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-8-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 956127-02-9 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[ (4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-1,2,4,5-tetrahydro-8-(1-methylethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 956127-28-9 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-8-(1-methylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 956140-80-0 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4'-(4-chlorophenyl)-1,1'-biphenyl]-4-yl]sulfonyl]amino]-1,2,4,5-tetrahydro-8-  
methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/583,590



RN 956141-98-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-1,2,4,5-tetrahydro-8-(1-methylethoxy)-, 1,1-dimethylethyl ester (CA INDEX NAME)



|                      |    |   |
|----------------------|----|---|
| OS.CITING REF COUNT: | 20 | THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)                                    |
| REFERENCE COUNT:     | 27 | THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT |

L17 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:570815 CAPLUS

DOCUMENT NUMBER: 143:97282

TITLE: Tetrahydrobenzazepines as dopamine D3 receptor modulators, their preparation, pharmaceutical compositions and use in the treatment of CNS disorders and renal function disorders

INVENTOR(S): Braje, Wilfried; Haupt, Andreas; Lubisch, Wilfried; Grandel, Roland; Drescher, Karla; Geneste, Herve; Unger, Liliane; Sauer, Daryl R.

PATENT ASSIGNEE(S): Abbott G.m.b.H. &amp;

Co. K.-G., Germany

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2005058328          | A1   | 20050630 | WO 2004-EP14428 | 20041217   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| US 20050137186         | A1   | 20050623 | US 2003-740092  | 20031218   |
| CA 2550053             | A1   | 20050630 | CA 2004-2550053 | 20041217   |
| EP 1694334             | A1   | 20060830 | EP 2004-820441  | 20041217   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS   |          |                 |            |
| JP 2007514696          | T  | 20070607 | JP 2006-544363  | 20041217   |
| MX 2006006858          | A  | 20060904 | MX 2006-6858    | 20060616   |
| US 20090105224         | A1   | 20090423 | US 2008-583590  | 20081212   |
| PRIORITY APPLN. INFO.: |  |          | US 2003-530806P | P 20031218 |
|                        |  |          | US 2003-740092  | A 20031218 |
|                        |  |          | WO 2004-EP14428 | W 20041217 |
| OTHER SOURCE(S):       | CASREACT 143:97282; MARPAT 143:97282   |          |                 |            |
| GI                     |  |          |                 |            |


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to tetrahydrobenzazepines I, which are selective modulators of dopamine D3 receptors. In compds. I, A is a bond or CH<sub>2</sub>; B is a bond or (un)substituted N; Y is a bond, CH<sub>2</sub>, or (un)substituted N, where A, B, and Y are not simultaneously a bond; Ar is (un)substituted aryl or (un)substituted 5- or 6-membered heteroaryl containing 1-4 heteroatoms

independently selected from O, N, and S; R1 is (un)substituted C1-8 alkyl, H, C1-8 haloalkyl, C2-8 alkenyl, etc.; and R2 is H, halo, C1-4 alkyl, C1-4 alkoxy, OH, nitro, cyano, etc.; including the corresponding N-oxides of I and all physiol. tolerated acid addition salts. The invention also relates to pharmaceutical compns. that comprise at least one tetrahydrobenzazepine I, the physiol. tolerated acid addition salt of I, the N-oxide of compound I and/or the physiol. tolerated acid addition salts of the N-oxides of I, together with physiol. acceptable carriers and/or excipients, as well as to the use of compound I for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 receptor agonists. The compds. of the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.

1,2-Benzenediacetic acid was esterified, followed by reduction, mesylation and heterocyclization with n-propylamine to give benzazepine II. II underwent carboxylation with oxalyl chloride and hydride reduction to give alc. III. Chlorination of III followed by substitution with (4-isopropyl)thiophenol, oxidation to the sulfone, and salt formation with hydrochloric acid resulted in the formation of compound IV. The compds. of the invention have a high affinity for dopamine D3 receptors with many of the compds. exhibiting Ki values lower than 5 nM, and many of them having a 100-fold selectivity for D3 receptors over D2L receptors [Ki(D2L)/Ki(D3)]. Compound IV has a Ki value for binding to dopamine D3 receptors of 1 nM and 446-fold selectivity for D3 over D2L.


- IT 583025-28-9P, 4-Isopropyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide 854679-46-2P,  
 N-(3-Propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-trifluoromethoxybenzenesulfonamide 854679-69-9P,  
 4-Isopropyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide hydrochloride 854681-16-6P,  
 N-[3-(Trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide 854681-32-6P,  
 N-[3-(Trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)benzenesulfonamide 854681-36-0P,  
 4-Isopropyl-N-[3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]benzenesulfonamide 854681-39-3P,  
 N-(2,3,4,5-Tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)benzenesulfonamide 854681-42-8P,  
 N-(2,3,4,5-Tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)benzenesulfonamide  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of tetrahydrobenzazepines as dopamine D3 receptor modulators)  
 RN 583025-28-9 CAPLUS  
 CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/583,590


RN 854679-46-2 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



RN 854679-69-9 CAPLUS


CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-16-6 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 854681-32-6 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)- (CA INDEX NAME)




RN 854681-36-0 CAPLUS

CN Benzenesulfonamide, 4-(1-methylethyl)-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 854681-39-3 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854681-42-8 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



IT 854679-50-8P, 4-Chloro-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide 854679-54-2P,  
N-(3-Propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-vinylbenzenesulfonamide hydrochloride 854679-58-6P,  
4-Ethyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide hydrochloride 854679-62-2P,  
N-(3-Propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-

(trifluoromethyl)benzenesulfonamide hydrochloride 854679-66-6P  
 , 4-tert-Butyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide hydrochloride 854679-73-5P,  
 N-(3-Propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide hydrochloride 854679-77-9P,  
 4-Acetyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide 854679-82-6P,  
 4-Methyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854679-87-1P,  
 2,4,6-Trimethyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854679-92-8P,  
 4-(1,1-Dimethylpropyl)-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854679-97-3P,  
 3-Chloro-4-methyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854680-02-7P,  
 4-Methoxy-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854680-07-2P,  
 N-(3-Propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)naphthalene-2-sulfonamide trifluoroacetate 854680-12-9P,  
 2,4-Dichloro-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854680-17-4P,  
 4-Bromo-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854680-23-2P,  
 4-Bromo-2-methyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854680-36-7P,  
 N-(3-Cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)benzenesulfonamide hydrochloride 854680-40-3P  
 , N-(3-Cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)benzenesulfonamide 854680-44-7P,  
 N-[3-(Cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)benzenesulfonamide hydrochloride 854680-48-1P  
 , N-[3-(Cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide 854680-52-7P,  
 N-[3-(1-Ethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)benzenesulfonamide hydrochloride 854680-56-1P  
 , N-[3-(1-Ethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854680-60-7P  
 , 4-(Trifluoromethoxy)-N-[3-(3,3,3-trifluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]benzenesulfonamide hydrochloride 854680-64-1P  
 , 4-(Trifluoromethyl)-N-[3-(3,3,3-trifluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]benzenesulfonamide 854680-69-6P,  
 4-Isopropyl-N-methyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate 854680-77-6P,  
 N-Methyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-trifluoromethoxybenzenesulfonamide 854680-81-2P,  
 N-Phenyl-3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonamide hydrochloride 854680-89-0P,  
 N-Methyl-N-phenyl-3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonamide hydrochloride 854680-93-6P,  
 3-Propyl-N-[4-(trifluoromethoxy)phenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonamide hydrochloride 854680-97-0P,  
 7-(4-Isopropylbenzenesulfonylmethyl)-3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine 854681-49-5P,  
 N-[3-(2-Methylbutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-56-4P  
 , N-[3-(4,4,4-Trifluorobutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide 854681-60-0P,

N-[3-(4,4,4-Trifluorobutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)benzenesulfonamide hydrochloride 854681-64-4P  
 , N-(3-Isobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-68-8P  
 , N-[3-(Cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-72-4P  
 , N-(3-Ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-76-8P  
 , N-[3-[3-(Cyclohexyloxy)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-80-4P  
 , N-[3-[3-(Cyclohexyloxy)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-isopropylbenzenesulfonamide hydrochloride 854681-84-8P,  
 N-[3-(2-Methoxyethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-88-2P  
 , N-[3-(3-Methoxypropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-92-8P  
 , N-[3-[2-(4-Fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854681-96-2P  
 , N-[3-(3-Phenylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-00-1P  
 , N-[3-(Cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-isopropylbenzenesulfonamide hydrochloride 854682-05-6P,  
 4-Isopropyl-N-(3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide hydrochloride 854682-08-9P,  
 N-(3-Cyclopropylmethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-isopropylbenzenesulfonamide hydrochloride 854682-12-5P,  
 N-(3-Allyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-19-2P  
 , N-(3-Prop-2-ynyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-23-8P  
 , N-[3-(3-Fluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-26-1P  
 , N-[3-(3-Phenoxypropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-31-8P  
 , N-[3-(2,2-Difluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-34-1P  
 , N-[3-(4-Fluorobutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-38-5P  
 , N-(3-Butyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)benzenesulfonamide hydrochloride 854682-41-0P  
 , N-(3-Allyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(isopropyl)benzenesulfonamide hydrochloride 854682-44-3P,  
 N-[3-(3-Fluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-isopropylbenzenesulfonamide hydrochloride 854682-46-5P,  
 N-[3-(2-Fluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide hydrochloride 856675-39-3P  
 , N-[4-[[3-(3-Propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)amino]sulfonyl]phenyl]acetamide hydrochloride 856675-42-8P,  
 4-Butyl-N-(3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)benzenesulfonamide trifluoroacetate  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of tetrahydrobenzazepines as dopamine D3 receptor modulators)


RN 854679-50-8 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-




10/583,590

benzazepin-7-yl)- (CA INDEX NAME)



RN 854679-54-2 CAPLUS


CN Benzenesulfonamide, 4-ethenyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854679-58-6 CAPLUS

CN Benzenesulfonamide, 4-ethyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854679-62-2 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854679-66-6 CAPLUS  
CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854679-73-5 CAPLUS  
CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854679-77-9 CAPLUS  
CN Benzenesulfonamide, 4-acetyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)


10/583,590



RN 854679-82-6 CAPLUS  
CN Benzenesulfonamide, 4-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 854679-81-5  
CMF C20 H26 N2 O2 S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 854679-87-1 CAPLUS  
CN Benzenesulfonamide, 2,4,6-trimethyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-86-0  
CMF C22 H30 N2 O2 S


10/583,590



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854679-92-8 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylpropyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-91-7


CMF C24 H34 N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




10/583,590

RN 854679-97-3 CAPLUS  
CN Benzenesulfonamide, 3-chloro-4-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 854679-96-2  
CMF C20 H25 Cl N2 O2 S



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 854680-02-7 CAPLUS  
CN Benzenesulfonamide, 4-methoxy-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 854680-01-6  
CMF C20 H26 N2 O3 S



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

10/583,590




RN 854680-07-2 CAPLUS

CN 2-Naphthalenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-06-1


CMF C23 H26 N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 854680-12-9 CAPLUS


CN Benzenesulfonamide, 2,4-dichloro-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-11-8

CMF C19 H22 Cl2 N2 O2 S


10/583,590



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854680-17-4 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-16-3


CMF C19 H23 Br N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 854680-23-2 CAPLUS

CN Benzenesulfonamide, 4-bromo-2-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-


10/583,590

benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-22-1


CMF C20 H25 Br N2 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 854680-36-7 CAPLUS

CN Benzenesulfonamide, N-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854680-40-3 CAPLUS

CN Benzenesulfonamide, N-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)




10/583,590



RN 854680-44-7 CAPLUS


CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854680-48-1 CAPLUS

CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854680-52-7 CAPLUS

CN Benzenesulfonamide, N-[3-(1-ethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

10/583,590

RN 854680-56-1 CAPLUS


CN Benzenesulfonamide, N-[3-(1-ethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854680-60-7 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3,3,3-trifluoropropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854680-64-1 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3,3,3-trifluoropropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 854680-69-6 CAPLUS

CN Benzenesulfonamide, N-methyl-4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


10/583,590

CRN 854680-68-5  
CMF C23 H32 N2 O2 S




CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 854680-77-6 CAPLUS  
CN Benzenesulfonamide, N-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)




RN 854680-81-2 CAPLUS  
CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-phenyl-3-propyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


10/583,590

RN 854680-89-0 CAPLUS  
CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-methyl-N-phenyl-3-propyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854680-93-6 CAPLUS  
CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-propyl-N-[4-(trifluoromethoxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854680-97-0 CAPLUS  
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[[4-(1-methylethyl)phenyl]sulfonyl]methyl]-3-propyl- (CA INDEX NAME)



RN 854681-49-5 CAPLUS  
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-methylbutyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl


RN 854681-56-4 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(4,4,4-trifluorobutyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854681-60-0 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(4,4,4-trifluorobutyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854681-64-4 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-methylpropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854681-68-8 CAPLUS  
CN Benzenesulfonamide, N-[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854681-72-4 CAPLUS  
CN Benzenesulfonamide, N-(3-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854681-76-8 CAPLUS  
CN Benzenesulfonamide, N-[3-[3-(cyclohexyloxy)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




10/583,590




● HCl

RN 854681-92-8 CAPLUS  
CN Benzenesulfonamide, N-[3-[2-(4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854681-96-2 CAPLUS  
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-phenylpropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854682-00-1 CAPLUS  
CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




10/583,590



● HCl

RN 854682-05-6 CAPLUS


CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854682-08-9 CAPLUS

CN Benzenesulfonamide, N-[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854682-12-5 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-propen-1-yl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-19-2 CAPLUS  
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-propyn-1-yl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-23-8 CAPLUS  
CN Benzenesulfonamide, N-[3-(3-fluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-26-1 CAPLUS  
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-phenoxypropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-31-8 CAPLUS  
CN Benzenesulfonamide, N-[3-(2,2-difluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-34-1 CAPLUS  
CN Benzenesulfonamide, N-[3-(4-fluorobutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-38-5 CAPLUS  
CN Benzenesulfonamide, N-(3-butyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-41-0 CAPLUS  
CN Benzenesulfonamide, 4-(1-methylethyl)-N-[2,3,4,5-tetrahydro-3-(2-propen-1-yl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-44-3 CAPLUS  
CN Benzenesulfonamide, N-[3-(3-fluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854682-46-5 CAPLUS  
CN Benzenesulfonamide, N-[3-(2-fluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl

RN 856675-39-3 CAPLUS

CN Acetamide, N-[4-[(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)amino]sulfonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 856675-42-8 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 583025-43-8

CMF C23 H32 N2 O2 S




CM 2


CRN 76-05-1

CMF C2 H F3 O2

10/583,590



IT 854682-48-7P, N-[3-(Fluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)benzenesulfonamide  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of tetrahydrobenzazepines as dopamine D3 receptor modulators)  
RN 854682-48-7 CAPLUS  
CN Benzenesulfonamide, N-[3-(2-fluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)  
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:547254 CAPLUS

DOCUMENT NUMBER: 143:59852

TITLE: A preparation of tetrahydrobenzazepine derivatives,  
useful as dopamine D3 receptor ligandsINVENTOR(S): Braje, Wilfried M.; Haupt, Andreas; Lubisch, Wilfried;  
Grandel, Roland; Drescher, Karla; Geneste, Herve;  
Unger, Liliane; Sauer, Daryl R.

PATENT ASSIGNEE(S): Abbott G.m.b.H. &amp;

Co. Kg., Germany

SOURCE: U.S. Pat. Appl. Publ., 23 pp.

CODEN: USXXCO



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE        |
|------------------------|--|----------|-----------------|-------------|
| US 20050137186         | A1   | 20050623 | US 2003-740092  | 20031218    |
| CA 2550053             | A1   | 20050630 | CA 2004-2550053 | 20041217    |
| WO 2005058328          | A1   | 20050630 | WO 2004-EP14428 | 20041217    |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |             |
| RW:                    | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |             |
| EP 1694334             | A1   | 20060830 | EP 2004-820441  | 20041217    |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS   |          |                 |             |
| JP 2007514696          | T  | 20070607 | JP 2006-544363  | 20041217    |
| EP 2332543             | A1   | 20110615 | EP 2010-193184  | 20041217    |
| R:                     | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV   |          |                 |             |
| MX 2006006858          | A  | 20060904 | MX 2006-6858    | 20060616    |
| US 20090105224         | A1   | 20090423 | US 2008-583590  | 20081212    |
| PRIORITY APPLN. INFO.: |  |          | US 2003-530806P | P 20031218  |
|                        |  |          | US 2003-740092  | A 20031218  |
|                        |  |          | EP 2004-820441  | A3 20041217 |
|                        |  |          | WO 2004-EP14428 | W 20041217  |
| OTHER SOURCE(S):       | CASREACT 143:59852; MARPAT 143:59852   |          |                 |             |
| GI                     |  |          |                 |             |



AB The invention relates to a preparation of tetrahydrobenzazepines of formula I [wherein: A is a single bond or CH<sub>2</sub>; B is a single bond, NH, or N(alkyl), etc.; Y is a single bond, CH<sub>2</sub>, NH, or n(alkyl), etc.; Ar is (hetero)aryl; R<sub>1</sub> is H, (halo)alkyl, or alk(en/yn)yl, etc.; R<sub>2</sub> is H, halogen, (halo)alkyl, or alkoxy, etc.], useful as dopamine D<sub>3</sub> receptor ligands. The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, phys. tolerated acid addition salt of I, N-oxide of compound of the formula I and/or phys. tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine D<sub>3</sub> receptor antagonists or dopamine D<sub>3</sub> agonists. The compds. according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders. For instance, tetrahydrobenzazepine derivative II [K<sub>i</sub>(D<sub>3</sub>) = 4.1 nM] was prepared via amidation of 4-chlorobenzenesulfonyl chloride by 3-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-amine.

IT 856675-42-8

RL: PRPH (Prophetic)

(A preparation of tetrahydrobenzazepine derivatives, useful as dopamine D<sub>3</sub> receptor ligands)

RN 856675-42-8 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 583025-43-8

CMF C23 H32 N2 O2 S







CM 2

CRN 76-05-1


CMF C2 H F3 O2



IT 854680-73-2P 854681-16-6P 854681-39-3P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of tetrahydrobenzazepine derivs. useful as selective dopamine D3 receptor ligands)  
 RN 854680-73-2 CAPLUS  
 CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 854681-16-6 CAPLUS  
 CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854681-39-3 CAPLUS

10/583,590

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)- (CA INDEX NAME)




|    |              |              |              |
|----|--------------|--------------|--------------|
| IT | 583025-28-9P | 854679-39-3P | 854679-46-2P |
|    | 854679-50-8P | 854679-54-2P | 854679-58-6P |
|    | 854679-62-2P | 854679-66-6P | 854679-69-9P |
|    | 854679-73-5P | 854679-77-9P | 854679-82-6P |
|    | 854679-87-1P | 854679-92-8P | 854679-97-3P |
|    | 854680-02-7P | 854680-07-2P | 854680-12-9P |
|    | 854680-17-4P | 854680-23-2P | 854680-36-7P |
|    | 854680-40-3P | 854680-44-7P | 854680-48-1P |
|    | 854680-52-7P | 854680-56-1P | 854680-60-7P |
|    | 854680-64-1P | 854680-69-6P | 854680-77-6P |
|    | 854680-81-2P | 854680-89-0P | 854680-93-6P |
|    | 854680-97-0P | 854681-12-2P | 854681-32-6P |
|    | 854681-36-0P | 854681-42-8P | 854681-49-5P |
|    | 854681-56-4P | 854681-60-0P | 854681-64-4P |
|    | 854681-68-8P | 854681-72-4P | 854681-76-8P |
|    | 854681-80-4P | 854681-84-8P | 854681-88-2P |
|    | 854681-92-8P | 854681-96-2P | 854682-00-1P |
|    | 854682-05-6P | 854682-08-9P | 854682-12-5P |
|    | 854682-19-2P | 854682-23-8P | 854682-26-1P |
|    | 854682-31-8P | 854682-34-1P | 854682-38-5P |
|    | 854682-41-0P | 854682-44-3P | 854682-46-5P |

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydrobenzazepine derivs. useful as selective dopamine D3 receptor ligands)

RN 583025-28-9 CAPLUS


CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 854679-39-3 CAPLUS


CN Acetamide, N-[4-[(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)amino]sulfonyl]phenyl]- (CA INDEX NAME)

10/583,590




RN 854679-46-2 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)




RN 854679-50-8 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 854679-54-2 CAPLUS

CN Benzenesulfonamide, 4-ethenyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854679-58-6 CAPLUS


CN Benzenesulfonamide, 4-ethyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854679-62-2 CAPLUS  
CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854679-66-6 CAPLUS  
CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854679-69-9 CAPLUS  
CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854679-73-5 CAPLUS  
CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854679-77-9 CAPLUS  
CN Benzenesulfonamide, 4-acetyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 854679-82-6 CAPLUS  
CN Benzenesulfonamide, 4-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-81-5  
CMF C20 H26 N2 O2 S


10/583,590



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854679-87-1 CAPLUS

CN Benzenesulfonamide, 2,4,6-trimethyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-86-0


CMF C22 H30 N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 854679-92-8 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylpropyl)-N-(2,3,4,5-tetrahydro-3-propyl-


10/583,590

1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-91-7


CMF C24 H34 N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854679-97-3 CAPLUS

CN Benzenesulfonamide, 3-chloro-4-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854679-96-2

CMF C20 H25 Cl N2 O2 S




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/583,590




RN 854680-02-7 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-01-6


CMF C20 H26 N2 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 854680-07-2 CAPLUS

CN 2-Naphthalenesulfonamide, N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 854680-06-1

CMF C23 H26 N2 O2 S




10/583,590



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854680-12-9 CAPLUS

CN Benzenesulfonamide, 2,4-dichloro-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-11-8


CMF C19 H22 Cl2 N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 854680-17-4 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-


10/583,590

7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-16-3


CMF C19 H23 Br N2 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 854680-23-2 CAPLUS

CN Benzenesulfonamide, 4-bromo-2-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-22-1

CMF C20 H25 Br N2 O2 S




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/583,590



RN 854680-36-7 CAPLUS


CN Benzenesulfonamide, N-(3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854680-40-3 CAPLUS

CN Benzenesulfonamide, N-(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



RN 854680-44-7 CAPLUS

CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854680-48-1 CAPLUS


10/583,590

CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854680-52-7 CAPLUS


CN Benzenesulfonamide, N-[3-(1-ethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854680-56-1 CAPLUS

CN Benzenesulfonamide, N-[3-(1-ethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854680-60-7 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3,3,3-trifluoropropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl

RN 854680-64-1 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3,3,3-trifluoropropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 854680-69-6 CAPLUS

CN Benzenesulfonamide, N-methyl-4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 854680-68-5

CMF C23 H32 N2 O2 S




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/583,590




RN 854680-77-6 CAPLUS

CN Benzenesulfonamide, N-methyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



RN 854680-81-2 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-phenyl-3-propyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854680-89-0 CAPLUS

CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-N-methyl-N-phenyl-3-propyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

10/583,590

RN 854680-93-6 CAPLUS


CN 1H-3-Benzazepine-7-sulfonamide, 2,3,4,5-tetrahydro-3-propyl-N-[4-(trifluoromethoxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854680-97-0 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[[4-(1-methylethyl)phenyl]sulfonyl]methyl]-3-propyl- (CA INDEX NAME)



RN 854681-12-2 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[[4-(1-methylethyl)phenyl]sulfonyl]methyl]-3-propyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854681-32-6 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)- (CA INDEX NAME)

10/583,590




RN 854681-36-0 CAPLUS

CN Benzenesulfonamide, 4-(1-methylethyl)-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 854681-42-8 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



RN 854681-49-5 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-methylbutyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-56-4 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(4,4,4-trifluorobutyl)-1H-3-




10/583,590

benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 854681-60-0 CAPLUS


CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(4,4,4-trifluorobutyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854681-64-4 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-methylpropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854681-68-8 CAPLUS

CN Benzenesulfonamide, N-[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl

RN 854681-72-4 CAPLUS


CN Benzenesulfonamide, N-(3-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854681-76-8 CAPLUS

CN Benzenesulfonamide, N-[3-[3-(cyclohexyloxy)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 854681-80-4 CAPLUS


CN Benzenesulfonamide, N-[3-[3-(cyclohexyloxy)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854681-84-8 CAPLUS  
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-methoxyethyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-88-2 CAPLUS  
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-methoxypropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854681-92-8 CAPLUS  
CN Benzenesulfonamide, N-[3-[2-(4-fluorophenyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854681-96-2 CAPLUS  
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-phenylpropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-00-1 CAPLUS  
CN Benzenesulfonamide, N-[3-(cyclohexylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-05-6 CAPLUS  
CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-08-9 CAPLUS  
CN Benzenesulfonamide, N-[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-12-5 CAPLUS  
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-propen-1-yl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-19-2 CAPLUS  
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(2-propyn-1-yl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-23-8 CAPLUS  
CN Benzenesulfonamide, N-[3-(3-fluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-26-1 CAPLUS  
CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-(3-phenoxypropyl)-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-31-8 CAPLUS  
CN Benzenesulfonamide, N-[3-(2,2-difluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-34-1 CAPLUS  
CN Benzenesulfonamide, N-[3-(4-fluorobutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-38-5 CAPLUS  
CN Benzenesulfonamide, N-(3-butyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 854682-41-0 CAPLUS  
CN Benzenesulfonamide, 4-(1-methylethyl)-N-[2,3,4,5-tetrahydro-3-(2-propen-1-yl)-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 854682-44-3 CAPLUS  
CN Benzenesulfonamide, N-[3-(3-fluoropropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(1-methylethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 854682-46-5 CAPLUS  
CN Benzenesulfonamide, N-[3-(2-fluoroethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 854682-48-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of tetrahydrobenzazepine derivs. useful as selective dopamine D<sub>3</sub> receptor ligands)  
RN 854682-48-7 CAPLUS  
CN Benzenesulfonamide, N-[3-(2-fluoroacetyl)-2,3,4,5-tetrahydro-1H-3-



10/583,590

benzazepin-7-yl]-4-(trifluoromethyl)- (CA INDEX NAME)



L17 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:913145 CAPLUS

DOCUMENT NUMBER: 139:395835

TITLE: Preparation of  
 N-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)  
 benzenesulfonamides as dopamine receptor modulators  
 for use as antipsychotic agents

INVENTOR(S): Gribble, Andrew Derrick; Forbes, Ian Thomson;  
 Lightfoot, Andrew; Payne, Andrew H.; Cooper, David  
 Gwyn

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2003095428          | A1   | 20031120 | WO 2003-GB1983  | 20030509   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| AU 2003227919          | A1   | 20031111 | AU 2003-227919  | 20030509   |
| EP 1503989             | A1   | 20050209 | EP 2003-725384  | 20030509   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |          |                 |            |
| JP 2005532318          | T  | 20051027 | JP 2004-503446  | 20030509   |
| US 20070043026         | A1   | 20070222 | US 2005-513919  | 20050523   |
| PRIORITY APPLN. INFO.: |  |          | GB 2002-10762   | A 20020510 |
|                        |  |          | WO 2003-GB1983  | W 20030509 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:395835

GI




AB The title compds. [I; A, B = (CH<sub>2</sub>)<sub>m</sub>, (CH<sub>2</sub>)<sub>n</sub>; R<sub>1</sub> = H, alkyl; R<sub>2</sub> = H, halo, OH, CN, NO<sub>2</sub>, alkyl, aryl, etc.; R<sub>3</sub> = H, alkyl; R<sub>4</sub> = (un)substituted (hetero)aryl; R<sub>5</sub>, R<sub>6</sub> = H, halo, OH, CN, NO<sub>2</sub>, alkyl, aryl, heteroaryl, etc.; m, n = 1-2; and either: Z = CR<sub>9</sub>R<sub>10</sub>X or XCR<sub>9</sub>R<sub>10</sub> and X = O, S, SO or SO<sub>2</sub>, or Z = CONR<sub>11</sub> or NR<sub>9</sub>CO and X = CH<sub>2</sub>, O, S, SO or SO<sub>2</sub>; R<sub>9</sub>, R<sub>10</sub> = H, alkyl, F; R<sub>11</sub> = H, alkyl] and their pharmaceutically acceptable salts, useful in therapy, in particular as antipsychotic agents, were prepared. Thus, amidation of 4-benzyloxybenzenesulfonyl chloride with tert-Bu 7-amino-8-bromo-1,2,4,5-tetrahydro-3-benzazepine-3-carboxylate (preparation given) followed by Boc-group removal afforded II. The compds. I have been found to exhibit affinity for dopamine receptors, in particular the D<sub>3</sub> and D<sub>2</sub> receptors (data given), and are useful in the treatment of disease states which require modulation of such receptors, such as psychotic conditions. Addnl., certain compds. I have antagonist affinity for the serotonin 5-HT<sub>2C</sub>, 5-HT<sub>2A</sub> and 5-HT<sub>6</sub> receptors (data given). Pharmaceutical composition comprising the compound I is claimed.


IT 625813-81-2P 625813-89-0P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of N-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl) benzenesulfonamides as dopamine receptor modulators for use as antipsychotic agents)

RN 625813-81-2 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenoxy)methyl]-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 625813-89-0 CAPLUS  
 CN Benzenesulfonamide, 4-[[ (4-chlorophenyl)amino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




|    |              |              |              |
|----|--------------|--------------|--------------|
| IT | 625813-02-7P | 625813-03-8P | 625813-04-9P |
|    | 625813-05-0P | 625813-06-1P | 625813-07-2P |
|    | 625813-08-3P | 625813-09-4P | 625813-12-9P |
|    | 625813-13-0P | 625813-14-1P | 625813-15-2P |
|    | 625813-16-3P | 625813-19-6P | 625813-20-9P |
|    | 625813-21-0P | 625813-22-1P | 625813-23-2P |
|    | 625813-24-3P | 625813-25-4P | 625813-26-5P |
|    | 625813-27-6P | 625813-28-7P | 625813-29-8P |
|    | 625813-30-1P | 625813-31-2P | 625813-32-3P |
|    | 625813-33-4P | 625813-34-5P | 625813-35-6P |
|    | 625813-38-9P | 625813-39-0P | 625813-45-8P |
|    | 625813-46-9P | 625813-47-0P | 625813-48-1P |
|    | 625813-50-5P | 625813-51-6P | 625813-59-4P |
|    | 625813-60-7P | 625813-61-8P | 625813-64-1P |
|    | 625813-65-2P | 625813-67-4P | 625813-68-5P |
|    | 625813-69-6P | 625813-70-9P | 625813-71-0P |
|    | 625813-72-1P | 625813-73-2P | 625813-74-3P |
|    | 625813-75-4P | 625813-79-8P | 625813-80-1P |
|    | 625813-82-3P | 625813-83-4P | 625813-84-5P |
|    | 625813-85-6P | 625813-86-7P | 625813-87-8P |
|    | 625813-88-9P | 625813-90-3P | 625813-91-4P |
|    | 625813-92-5P | 625813-93-6P | 625813-94-7P |
|    | 625813-95-8P | 625813-96-9P | 625813-97-0P |
|    | 625813-98-1P | 625813-99-2P | 625814-01-9P |
|    | 625814-02-0P | 625814-03-1P | 625814-04-2P |
|    | 625814-05-3P |              |              |

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl) benzenesulfonamides as dopamine receptor modulators for use as antipsychotic agents)


RN 625813-02-7 CAPLUS  
 CN Benzenesulfonamide, 4-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 625813-03-8 CAPLUS

CN Benzenesulfonamide, 4-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-04-9 CAPLUS

CN Benzenesulfonamide, N-(8-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(phenylmethoxy)- (CA INDEX NAME)



RN 625813-05-0 CAPLUS


CN Benzenesulfonamide, N-(8-ethyl-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(phenylmethoxy)- (CA INDEX NAME)



RN 625813-06-1 CAPLUS


CN Benzenesulfonamide, 4-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 625813-07-2 CAPLUS

CN Benzenesulfonamide, 4-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-08-3 CAPLUS

CN Benzenesulfonamide, 4-[(4-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-09-4 CAPLUS


CN Benzenesulfonamide, 4-[(4-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-12-9 CAPLUS


CN Benzenesulfonamide, 4-[(4-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 625813-13-0 CAPLUS

CN Benzenesulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(phenylmethoxy)- (CA INDEX NAME)




RN 625813-14-1 CAPLUS

CN Benzenesulfonamide, N-(9-bromo-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(phenylmethoxy)- (CA INDEX NAME)



RN 625813-15-2 CAPLUS


CN Benzenesulfonamide, 3-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-16-3 CAPLUS


CN Benzenesulfonamide, 3-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 625813-19-6 CAPLUS

CN Benzenesulfonamide, 3-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-20-9 CAPLUS

CN Benzenesulfonamide, 3-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-21-0 CAPLUS


CN Benzenesulfonamide, N-methyl-3-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-22-1 CAPLUS


CN Benzenesulfonamide, 3-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)






RN 625813-23-2 CAPLUS

CN Benzenesulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-3-(phenylmethoxy)- (CA INDEX NAME)




RN 625813-24-3 CAPLUS

CN Benzenesulfonamide, 4-[(3-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-25-4 CAPLUS


CN Benzenesulfonamide, 4-[(3-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-26-5 CAPLUS


CN Benzenesulfonamide, 4-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 625813-27-6 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-28-7 CAPLUS

CN Benzenesulfonamide, 4-[(2-methylphenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-29-8 CAPLUS

CN Benzenesulfonamide, 4-[(2-methylphenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-30-1 CAPLUS

CN Benzenesulfonamide, 4-[(3-methylphenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-31-2 CAPLUS

CN Benzenesulfonamide, 4-[(3-methylphenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-32-3 CAPLUS

CN Benzenesulfonamide, 4-[(3,4-difluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-33-4 CAPLUS


CN Benzenesulfonamide, 4-[(3,4-difluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-34-5 CAPLUS


CN Benzenesulfonamide, 4-[(2,4-difluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 625813-35-6 CAPLUS

CN Benzenesulfonamide, 4-[(2,4-difluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-38-9 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-39-0 CAPLUS


CN Benzenesulfonamide, 4-[(2-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-45-8 CAPLUS


CN Benzenesulfonamide, 4-[(2-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 625813-46-9 CAPLUS

CN Benzenesulfonamide, 4-[(3-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-47-0 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-[[4-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)




RN 625813-48-1 CAPLUS

CN Benzenesulfonamide, 4-[(4-methylphenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-50-5 CAPLUS

CN Benzenesulfonamide, 4-(phenylmethoxy)-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-51-6 CAPLUS

CN Benzenesulfonamide, 4-[(3-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-59-4 CAPLUS

CN Benzenesulfonamide, 3-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-60-7 CAPLUS

CN Benzenesulfonamide, 3-[(4-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-61-8 CAPLUS

CN Benzenesulfonamide, 3-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-64-1 CAPLUS

CN Benzenesulfonamide, 2-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-65-2 CAPLUS

CN Benzenesulfonamide, 2-[(4-fluorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-67-4 CAPLUS


CN Benzenesulfonamide, 2-[(4-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/583,590


RN 625813-68-5 CAPLUS

CN Benzenesulfonamide, 2-[(4-chlorophenyl)methoxy]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-69-6 CAPLUS

CN Benzenesulfonamide, 2-(phenylmethoxy)-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 625813-70-9 CAPLUS

CN Benzenesulfonamide, 4-[(4-chlorophenoxy)methyl]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-71-0 CAPLUS

CN Benzenesulfonamide, 4-(phenoxymethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)






10/583,590


RN 625813-72-1 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenoxy)methyl]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-73-2 CAPLUS

CN Benzenesulfonamide, 4-(phenoxy)methyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-74-3 CAPLUS

CN Benzenesulfonamide, 4-[(4-chlorophenoxy)methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-75-4 CAPLUS


CN Benzenesulfonamide, 4-[(4-fluorophenoxy)methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-79-8 CAPLUS


CN Benzenesulfonamide, 4-(phenoxy)methyl)-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 625813-80-1 CAPLUS

CN Benzenesulfonamide, 4-[(4-chlorophenoxy)methyl]-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 625813-82-3 CAPLUS

CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)methyl]amino]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-83-4 CAPLUS


CN Benzenesulfonamide, 4-[[[(4-chlorophenyl)methyl]amino]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-84-5 CAPLUS


CN Benzenesulfonamide, 4-[[[(4-methoxyphenyl)methyl]amino]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 625813-85-6 CAPLUS

CN Benzenesulfonamide, 4-[[[(4-cyanophenyl)methyl]amino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-86-7 CAPLUS

CN Benzenesulfonamide, 4-[[[(4-acetylphenyl)methyl]amino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-87-8 CAPLUS


CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)methyl]amino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625813-88-9 CAPLUS


CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)amino]methyl]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:?) (CA INDEX NAME)

10/583,590




●x HCl

RN 625813-90-3 CAPLUS  
CN Benzenesulfonamide, 4-[[4-(4-methoxyphenyl)amino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-91-4 CAPLUS  
CN Benzenesulfonamide, 4-[[4-(4-fluorophenyl)methylamino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 625813-92-5 CAPLUS  
CN Benzenesulfonamide, 4-[[4-(4-chlorophenyl)methylamino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 625813-93-6 CAPLUS

CN Benzenesulfonamide, 4-[[4-(4-methoxyphenyl)methylamino]methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625813-94-7 CAPLUS

CN Benzenesulfonamide, N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4-[(4-fluorophenyl)methoxy]- (CA INDEX NAME)



RN 625813-95-8 CAPLUS


CN Benzenesulfonamide, N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4-[(3-fluorophenyl)methoxy]- (CA INDEX NAME)



RN 625813-96-9 CAPLUS


CN Benzenesulfonamide, N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4-[[4-(trifluoromethyl)phenyl]methoxy]- (CA INDEX NAME)

10/583,590



RN 625813-97-0 CAPLUS


CN Benzenesulfonamide, N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4-[[4-(4-fluorophenyl)methyl]methylamino]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 625813-98-1 CAPLUS


CN Benzenesulfonamide, 4-[[4-(4-chlorophenyl)methyl]methylamino]-N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 625813-99-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-(4-chlorophenyl)methylamino]methyl]-N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 625814-01-9 CAPLUS  
CN Benzenesulfonamide, 4-[(4-chlorophenoxy)methyl]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 625814-02-0 CAPLUS  
CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)methyl]amino]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:?) (CA INDEX NAME)



●<sub>x</sub> HCl


RN 625814-03-1 CAPLUS  
CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)methyl]methylamino]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:?) (CA INDEX NAME)

10/583,590




●x HCl

RN 625814-04-2 CAPLUS  
CN Benzenesulfonamide, N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4-[(4-fluorophenyl)methoxy]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 625814-05-3 CAPLUS  
CN Benzenesulfonamide, 4-[[[(4-chlorophenyl)methylamino]methyl]-N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

|    |              |              |              |
|----|--------------|--------------|--------------|
| IT | 625814-07-5P | 625814-08-6P | 625814-09-7P |
|    | 625814-10-0P | 625814-11-1P | 625814-12-2P |
|    | 625814-13-3P | 625814-14-4P | 625814-15-5P |
|    | 625814-16-6P | 625814-17-7P | 625814-18-8P |
|    | 625814-19-9P | 625814-20-2P |              |




RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-(2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl) benzenesulfonamides as dopamine receptor modulators for use as antipsychotic agents)


RN 625814-07-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-methoxy-8-[[ (4-nitrophenyl)sulfonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 625814-08-6 CAPLUS


CN Benzenesulfonamide, 4-nitro-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 625814-09-7 CAPLUS

CN Benzenesulfonamide, 4-nitro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625814-10-0 CAPLUS

CN Benzenesulfonamide, 4-amino-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 625814-11-1 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4-(bromomethyl)phenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-8-methoxy-,  
1,1-dimethylethyl ester (CA INDEX NAME)




RN 625814-12-2 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4-[[[4-(4-fluorophenyl)amino]methyl]phenyl]sulfonyl]amino]-1,2,4,5-  
tetrahydro-8-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 625814-13-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4-(4-carboxyphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-,  
3-(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 625814-14-4 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,  
1,2,4,5-tetrahydro-7-[[[4-(hydroxymethyl)phenyl]sulfonyl]amino]-,

10/583,590


1,1-dimethylethyl ester (CA INDEX NAME)



RN 625814-15-5 CAPLUS  
CN 3H-3-Benzazepine-3-carboxylic acid,  
1,2,4,5-tetrahydro-7-[[[4-  
[(methylsulfonyl)oxy]methyl]phenyl]sulfonyl]amino]-, 1,1-dimethylethyl  
ester (CA INDEX NAME)




RN 625814-16-6 CAPLUS  
CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4-[(4-chlorophenoxy)methyl]phenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-  
, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 625814-17-7 CAPLUS  
CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4-(4-carboxyphenyl)sulfonyl]amino]-8-(dimethylamino)-1,2,4,5-tetrahydro-  
, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)


10/583,590



RN 625814-18-8 CAPLUS  
CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4-[[[(4-chlorophenyl)methylamino]carbonyl]phenyl]sulfonyl]amino]-8-(  
(dimethylamino)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX  
NAME)




RN 625814-19-9 CAPLUS  
CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)methyl]formylamino]-N-(2,3,4,5-  
tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 625814-20-2 CAPLUS  
CN Benzenesulfonamide, 4-[[[(4-fluorophenyl)amino]methyl]-N-(2,3,4,5-  
tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA  
INDEX NAME)

10/583,590



● HCl

|                      |   |  |
|----------------------|---|--|
| OS.CITING REF COUNT: | 6 | THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)                                     |
| REFERENCE COUNT:     | 4 | THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT |

L17 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:656751 CAPLUS

DOCUMENT NUMBER: 139:197391

TITLE: Preparation of N-heterocyclyl benzenesulfonamides as antipsychotic agents

INVENTOR(S): Bromidge, Steven Mark; Cooper, David Gwyn; Forbes, Ian Thomson; Gribble, Andrew Derrick; Johnson, Christopher Norbert; Lightfoot, Andrew P.; Moss, Stephen Frederick; Payne, Andrew H.; Rahman, Shahzad Sharooq; Witty, David R.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2




PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2003068752          | A1   | 20030821 | WO 2003-EP1545  | 20030213   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| CA 2475783             | A1   | 20030821 | CA 2003-2475783 | 20030213   |
| AU 2003215558          | A1   | 20030904 | AU 2003-215558  | 20030213   |
| EP 1474399             | A1   | 20041110 | EP 2003-739495  | 20030213   |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |          |                 |            |
| BR 2003007557          | A  | 20050104 | BR 2003-7557    | 20030213   |
| CN 1630642             | A  | 20050622 | CN 2003-803746  | 20030213   |
| JP 2005526724          | T  | 20050908 | JP 2003-567883  | 20030213   |
| IN 2004DN02106         | A  | 20050401 | IN 2004-DN2106  | 20040721   |
| MX 2004007920          | A  | 20041126 | MX 2004-7920    | 20040813   |
| NO 2004003794          | A  | 20040910 | NO 2004-3794    | 20040910   |
| US 20050222124         | A1   | 20051006 | US 2005-504111  | 20050315   |
| ZA 2004005804          | A  | 20060531 | ZA 2004-5804    | 20060317   |
| PRIORITY APPLN. INFO.: |  |          | GB 2002-3437    | A 20020213 |
|                        |  |          | GB 2002-3438    | A 20020213 |
|                        |  |          | GB 2002-4758    | A 20020228 |
|                        |  |          | GB 2002-4784    | A 20020228 |
|                        |  |          | GB 2002-12548   | A 20020530 |
|                        |  |          | GB 2002-19711   | A 20020823 |
|                        |  |          | GB 2002-24466   | A 20021021 |
|                        |  |          | WO 2003-EP1545  | W 20030213 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:197391

GI



AB The title compds. [I; A and B = (CH<sub>2</sub>)<sub>m</sub> and (CH<sub>2</sub>)<sub>n</sub>, resp.; R<sub>1</sub> = H, alkyl; R<sub>2</sub> = H, halo, OH, CN, etc.; R<sub>3</sub> = H, alkyl; Ar = (un)substituted Ph, monocyclic heteroaryl; R<sub>4</sub> = (un)substituted aryl or heteroaryl; Z = a bond, O, alkyl; Y = H, alkyl; m, n = 1-2; q = 1-3; r = 1-4] and their pharmaceutically acceptable salts, useful in therapy, in particular as antipsychotic agents, were prepared Thus, amidation of the amine II (preparation


given) with 4'-chloro-biphenyl-4-sulfonyl chloride followed by trifluoroacetyl group removal afforded III. The exemplified compds. I have pK<sub>i</sub> values within the range of 6.6-9.6 at the dopamine D<sub>3</sub> receptor, and pK<sub>i</sub> values within the range of 5.3-9.3 at the dopamine D<sub>2</sub> receptor. Pharmaceutical composition comprising the compound I was claimed.

IT 583044-69-3P 583044-71-7P 583045-10-7P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of benzenesulfonamides as antipsychotic agents)

RN 583044-69-3 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583044-71-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-10-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

|    |              |              |              |
|----|--------------|--------------|--------------|
| IT | 583044-70-6P | 583044-72-8P | 583044-73-9P |
|    | 583044-74-0P | 583044-75-1P | 583044-80-8P |
|    | 583044-81-9P | 583044-82-0P | 583044-83-1P |
|    | 583044-84-2P | 583044-85-3P | 583044-86-4P |
|    | 583044-87-5P | 583044-88-6P | 583044-89-7P |
|    | 583044-90-0P | 583044-91-1P | 583044-92-2P |
|    | 583044-93-3P | 583044-94-4P | 583044-95-5P |
|    | 583044-96-6P | 583044-97-7P | 583044-98-8P |
|    | 583044-99-9P | 583045-00-5P | 583045-01-6P |
|    | 583045-02-7P | 583045-03-8P | 583045-04-9P |
|    | 583045-05-0P | 583045-06-1P | 583045-07-2P |
|    | 583045-08-3P | 583045-09-4P | 583045-11-8P |
|    | 583045-12-9P | 583045-13-0P | 583045-43-6P |
|    | 583045-44-7P | 583045-45-8P | 583045-46-9P |
|    | 583045-47-0P | 583045-48-1P | 583045-49-2P |
|    | 583045-50-5P | 583045-51-6P | 583045-52-7P |
|    | 583045-53-8P | 583045-54-9P | 583045-55-0P |
|    | 583045-56-1P | 583045-57-2P | 583045-58-3P |




|              |              |              |
|--------------|--------------|--------------|
| 583045-59-4P | 583045-60-7P | 583045-61-8P |
| 583045-62-9P | 583045-63-0P | 583045-64-1P |
| 583045-65-2P | 583045-66-3P | 583045-67-4P |
| 583045-68-5P | 583045-69-6P | 583045-70-9P |
| 583045-71-0P | 583045-72-1P | 583045-73-2P |
| 583045-74-3P | 583045-75-4P | 583045-76-5P |
| 583045-77-6P | 583045-78-7P | 583045-79-8P |
| 583045-80-1P | 583045-81-2P | 583045-82-3P |
| 583045-83-4P | 583045-84-5P | 583045-85-6P |
| 583045-86-7P | 583045-87-8P | 583045-88-9P |
| 583045-89-0P | 583045-90-3P | 583045-91-4P |
| 583045-92-5P | 583045-94-7P | 583045-95-8P |
| 583045-96-9P | 583045-98-1P | 583046-00-8P |
| 583046-03-1P | 583046-05-3P | 583046-08-6P |
| 583046-11-1P | 583046-13-3P | 583046-15-5P |
| 583046-17-7P | 583046-19-9P | 583046-21-3P |
| 583046-23-5P | 583046-24-6P | 583046-26-8P |
| 583046-27-9P | 583046-30-4P | 583046-31-5P |
| 583046-32-6P | 583046-34-8P | 583046-35-9P |
| 583046-36-0P | 583046-37-1P | 583046-38-2P |
| 583046-39-3P | 583046-40-6P | 583046-41-7P |
| 583046-42-8P | 583046-63-3P | 583046-69-9P |
| 583046-72-4P | 583046-73-5P | 583046-74-6P |
| 583046-75-7P | 583046-76-8P | 583046-77-9P |
| 583046-78-0P | 583046-79-1P | 583046-80-4P |
| 583046-81-5P | 583046-82-6P | 583046-83-7P |
| 583046-86-0P | 583046-87-1P | 583046-88-2P |
| 583046-90-6P | 583046-91-7P | 583046-92-8P |
| 583046-93-9P | 583046-94-0P | 583046-95-1P |
| 583046-96-2P | 583046-97-3P | 583046-98-4P |
| 583046-99-5P | 583047-00-1P | 583047-01-2P |
| 583047-04-5P | 583047-05-6P | 583047-47-6P |

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzenesulfonamides as antipsychotic agents)

RN 583044-70-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-72-8 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590



RN 583044-73-9 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 3',4'-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 583044-74-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 583044-75-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl


RN 583044-80-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 2'-chloro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-81-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3'-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-82-0 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 3'-chloro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-83-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 3',4'-dichloro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583044-84-2 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 2',4'-dichloro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-85-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-bromo-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-86-4 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-bromo-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-87-5 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583044-88-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3'-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-89-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3'-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-90-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 2'-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-91-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 2'-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-92-2 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4'-(trifluoromethyl)- (CA INDEX NAME)




RN 583044-93-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4'-(trifluoromethoxy)- (CA INDEX NAME)



RN 583044-94-4 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-(methylthio)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-95-5 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-(1,1-dimethylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583044-96-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583044-97-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-98-8 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-methoxy-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583044-99-9 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-00-5 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(2-thienyl)- (CA INDEX NAME)




RN 583045-01-6 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-02-7 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(3-thienyl)- (CA INDEX NAME)




RN 583045-03-8 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(3-thienyl)- (CA INDEX NAME)




10/583,590




RN 583045-04-9 CAPLUS

CN Benzenesulfonamide, 4-(2-naphthalenyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-05-0 CAPLUS

CN Benzenesulfonamide, 4-(2-benzofuranyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-06-1 CAPLUS


CN Benzenesulfonamide, 4-(4-pyridinyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-07-2 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(3-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-08-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-09-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-3-(1-methylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583045-11-8 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-12-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl


RN 583045-13-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-43-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-nitro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-44-7 CAPLUS


CN Benzenesulfonamide, 4-(3-furanyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-45-8 CAPLUS


10/583,590

CN Benzenesulfonamide, 4-(3-furanyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-46-9 CAPLUS

CN Benzenesulfonamide, 4-(4-chlorophenoxy)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-47-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-48-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-49-2 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 3'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-50-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-51-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 3',4'-dichloro-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-52-7 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 3',4'-dichloro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-53-8 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 2',4'-dichloro-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-54-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 2',4'-dichloro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-55-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2'-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-56-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2'-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-57-2 CAPLUS


10/583,590

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-58-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-59-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 583045-60-7 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-4'-(trifluoromethyl)- (CA INDEX NAME)



RN 583045-61-8 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-4'-(trifluoromethoxy)- (CA INDEX NAME)

10/583,590




RN 583045-62-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-4'-(trifluoromethoxy)- (CA INDEX NAME)




RN 583045-63-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-methoxy-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-64-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-methoxy-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-65-2 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




10/583,590




RN 583045-66-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-67-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-(dimethylamino)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-68-5 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-(dimethylamino)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-69-6 CAPLUS


CN Benzenesulfonamide, 4-phenoxy-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-70-9 CAPLUS

CN Benzenesulfonamide, 4-phenoxy-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-71-0 CAPLUS

CN Benzenesulfonamide, 4-(4-chlorophenoxy)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-72-1 CAPLUS


CN Benzenesulfonamide, 4-(4-chlorophenoxy)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-73-2 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-4-(2-thienyl)- (CA INDEX NAME)

10/583,590




RN 583045-74-3 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-4-(2-thienyl)- (CA INDEX NAME)




RN 583045-75-4 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-76-5 CAPLUS


CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-77-6 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-4-(3-thienyl)- (CA INDEX NAME)

10/583,590




RN 583045-78-7 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-4-(3-thienyl)- (CA INDEX NAME)




RN 583045-79-8 CAPLUS

CN Benzenesulfonamide, 4-(3-furanyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-80-1 CAPLUS


CN Benzenesulfonamide, 4-(3-furanyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-81-2 CAPLUS


CN Benzenesulfonamide, 4-(4-pyridinyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-82-3 CAPLUS

CN Benzenesulfonamide, 4-(4-pyridinyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-83-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-fluoro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-84-5 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-fluoro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583045-85-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 2,4'-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583045-86-7 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(8-ethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-87-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(8-ethoxy-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583045-88-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583045-89-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583045-90-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(8-ethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-methyl- (CA INDEX NAME)




RN 583045-91-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(8-ethoxy-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-2-methyl- (CA INDEX NAME)



RN 583045-92-5 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583045-94-7 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-methyl-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 583045-95-8 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]-4-(2-thienyl)- (CA INDEX NAME)




RN 583045-96-9 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]-4-(3-thienyl)- (CA INDEX NAME)



RN 583045-98-1 CAPLUS

CN Benzenesulfonamide, 4-(3-furanyl)-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-00-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




10/583,590




RN 583046-03-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-methoxy-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-05-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]-4'-(trifluoromethoxy)- (CA INDEX NAME)



RN 583046-08-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2'-methyl-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583046-11-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-3'-methyl-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 583046-13-3 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]-4-(2-thienyl)- (CA INDEX NAME)




RN 583046-15-5 CAPLUS

CN Benzenesulfonamide, N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]-4-(3-thienyl)- (CA INDEX NAME)




RN 583046-17-7 CAPLUS

CN Benzenesulfonamide, 4-(3-furanyl)-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-19-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-21-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-methoxy-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-23-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]-4'-(trifluoromethoxy)- (CA INDEX NAME)




RN 583046-24-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2'-methyl-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-26-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-3'-methyl-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-27-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-3-fluoro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-30-4 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-2-fluoro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-31-5 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-2-(trifluoromethyl)- (CA INDEX NAME)



RN 583046-32-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583046-34-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-35-9 CAPLUS

CN Benzenesulfonamide, N-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4-(3-thienyl)- (CA INDEX NAME)



RN 583046-36-0 CAPLUS


CN Benzenesulfonamide, N-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(3-thienyl)- (CA INDEX NAME)



RN 583046-37-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583046-38-2 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-cyano-N-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-39-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-40-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-41-7 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583046-42-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-63-3 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-69-9 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-2-furanyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-72-4 CAPLUS

CN Benzenesulfonamide, 4-(5-methyl-2-furanyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-73-5 CAPLUS

CN Benzenesulfonamide, 4-(4-methyl-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-74-6 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[4-[[ (2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)amino]sulfonyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 583046-75-7 CAPLUS

CN 1H-Pyrrole-1-carboxylic acid, 2-[4-[[ (2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)amino]sulfonyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 583046-76-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(8-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-4'-fluoro- (CA INDEX NAME)




10/583,590




RN 583046-77-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(8-ethyl-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-78-0 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(8-ethyl-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4'-fluoro- (CA INDEX NAME)



RN 583046-79-1 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 3',4'-difluoro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-80-4 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 2'-fluoro-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583046-81-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(8-ethyl-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-2'-fluoro-N-(1-methylethyl)- (CA INDEX NAME)




RN 583046-82-6 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[8-(ethylthio)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583046-83-7 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-86-0 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4'-fluoro- (CA INDEX NAME)

10/583,590




RN 583046-87-1 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583046-88-2 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3,8-dimethyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-90-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, N-[8-(ethylthio)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]-4'-fluoro- (CA INDEX NAME)



RN 583046-91-7 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-fluoro-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-piperidinyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 583046-92-8 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4'-fluoro- (CA INDEX NAME)




RN 583046-93-9 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, N-(9-bromo-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4'-fluoro- (CA INDEX NAME)



RN 583046-94-0 CAPLUS


CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(3-ethyl-2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-95-1 CAPLUS


CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-[2,3,4,5-tetrahydro-8-methoxy-3-(1-methylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 583046-96-2 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-[2,3,4,5-tetrahydro-8-methoxy-3-(2-methylpropyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583046-97-3 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-[2,3,4,5-tetrahydro-8-methoxy-3-(phenylmethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583046-98-4 CAPLUS


CN Benzenesulfonamide, 4-[(4-fluorophenyl)methyl]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583046-99-5 CAPLUS

CN Benzenesulfonamide, 4-[(3-fluorophenyl)methyl]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583047-00-1 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenyl)methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583047-01-2 CAPLUS

CN Benzenesulfonamide, 4-[(3-fluorophenyl)methyl]-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583047-04-5 CAPLUS


CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-2-fluoro-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583047-05-6 CAPLUS


CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[8-(dimethylamino)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590



RN 583047-47-6 CAPLUS

CN Benzenesulfonamide, 4-[(4-fluorophenyl)methyl]-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


|    |              |              |              |
|----|--------------|--------------|--------------|
| IT | 583047-07-8P | 583047-33-0P | 583047-34-1P |
|    | 583047-35-2P | 583047-36-3P | 583047-38-5P |
|    | 583047-40-9P | 583047-41-0P | 583047-42-1P |
|    | 583047-43-2P | 583047-44-3P | 583047-45-4P |
|    | 583047-46-5P |              |              |

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzenesulfonamides as antipsychotic agents)

RN 583047-07-8 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[4-iodophenyl)sulfonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 583047-33-0 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[4-iodophenyl)sulfonyl]amino]-8-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/583,590




RN 583047-34-1 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4-[(4-fluorophenyl)methyl]phenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-,  
1,1-dimethylethyl ester (CA INDEX NAME)



RN 583047-35-2 CAPLUS


CN Benzenesulfonamide, 4-[(4-fluorophenyl)methyl]-N-(2,3,4,5-tetrahydro-1H-3-  
benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 583047-36-3 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[2,3,4,5-tetrahydro-3-(2,2,2-  
trifluoroacetyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583047-38-5 CAPLUS




10/583,590


CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[ (3',4'-dichloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-1,2,4,5-tetrahydro-  
, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 583047-40-9 CAPLUS  
CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4-(5-chloro-2-thienyl)phenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-8-  
methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 583047-41-0 CAPLUS  
CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-N-(2,3,4,5-tetrahydro-8-methoxy-  
1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 583047-42-1 CAPLUS  
CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[ (2-fluoro-4-iodophenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-8-methoxy-,  
1,1-dimethylethyl ester (CA INDEX NAME)

10/583,590




RN 583047-43-2 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4-(5-chloro-2-thienyl)-2-fluorophenyl]sulfonyl]amino]-1,2,4,5-  
tetrahydro-8-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 583047-44-3 CAPLUS

CN Benzenesulfonamide, 4-(5-chloro-2-thienyl)-2-fluoro-N-(2,3,4,5-tetrahydro-  
8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 583047-45-4 CAPLUS


CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4'-(chloro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-8-(dimethylamino)-  
1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/583,590



RN 583047-46-5 CAPLUS

CN [1,1'-Biphenyl]-4-sulfonamide, 4'-chloro-N-[8-(dimethylamino)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

|                      |    |  |
|----------------------|----|--|
| OS.CITING REF COUNT: | 13 | THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)                                   |
| REFERENCE COUNT:     | 3  | THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT |

L17 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:656750 CAPLUS

DOCUMENT NUMBER: 139:197390

TITLE: Preparation of  
7-arylsulfonamido-2,3,4,5-tetrahydro-1H-  
benzo[d]azepines with 5-HT6 receptor affinity for the  
treatment of CNS disorders

INVENTOR(S): Bromidge, Steven Mark; Johnson, Christopher Norbert;  
Moss, Stephen Frederick; Rahman, Shahzad Sharooq;  
Witty, David R.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE     | APPLICATION NO. | DATE       |
|------------------------|--|----------|-----------------|------------|
| WO 2003068751          | A1   | 20030821 | WO 2003-EP1543  | 20030213   |
| W:                     | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |          |                 |            |
| RW:                    | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG   |          |                 |            |
| AU 2003206909          | A1   | 20030904 | AU 2003-206909  | 20030213   |
| EP 1487801             | A1   | 20041222 | EP 2003-704631  | 20030213   |
| EP 1487801             | B1   | 20060419 |                 |            |
| R:                     | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |          |                 |            |
| JP 2005522452          | T  | 20050728 | JP 2003-567882  | 20030213   |
| AT 323680              | T  | 20060515 | AT 2003-704631  | 20030213   |
| ES 2260607             | T3   | 20061101 | ES 2003-704631  | 20030213   |
| US 20050090485         | A1   | 20050428 | US 2004-503678  | 20040804   |
| PRIORITY APPLN. INFO.: |  |          | GB 2002-3437    | A 20020213 |
|                        |  |          | GB 2002-4758    | A 20020228 |
|                        |  |          | GB 2002-12548   | A 20020530 |
|                        |  |          | GB 2002-19711   | A 20020823 |
|                        |  |          | WO 2003-EP1543  | W 20030213 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:197390

GI



AB The title compds. [I; R1 = H, halo, OH, etc.; R2 = H, alkyl; m = 1-3; n = 1-4; A = (un)substituted Ph, naphthyl, monocyclic or bicyclic heteroaryl] and their pharmaceutically acceptable salts, useful in the treatment of CNS and other disorders such as depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment and schizophrenia, were prepared E.g., a 4-step synthesis of I.HCl [R1, R2 = H; A = 3-F3CC6H4], starting from 7-nitro-2,3,4,5-tetrahydro-1H-benzo[d]azepine, was given. The exemplified compds. I were tested and showed good affinity for the 5-HT6 receptor, having pKi values > 8 at human cloned 5-HT6 receptors. Pharmaceutical composition comprising the title compound I was claimed.


IT 585570-54-3P      585570-55-4P      585570-56-5P  
 585570-58-7P      585570-59-8P      585570-60-1P  
 585570-61-2P      585570-62-3P      585570-63-4P  
 585570-64-5P      585570-65-6P      585570-66-7P  
 585570-67-8P      585570-68-9P      585570-69-0P  
 585570-70-3P      585570-83-8P      585570-84-9P  
 585570-85-0P      585570-87-2P      585570-88-3P  
 585570-89-4P      585570-90-7P      585570-91-8P  
 585570-92-9P      585570-93-0P      585570-94-1P  
 585570-95-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 7-arylsulfonamido-2,3,4,5-tetrahydro-1H-benzo[d]azepines with 5-HT6 receptor affinity for the treatment of CNS disorders)

RN 585570-54-3 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 585570-55-4 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 585570-56-5 CAPLUS  
CN Benzenesulfonamide, 3-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 585570-58-7 CAPLUS  
CN Benzenesulfonamide, 4-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 585570-59-8 CAPLUS  
CN Benzenesulfonamide, 4-bromo-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethoxy)- (CA INDEX NAME)

10/583,590



RN 585570-60-1 CAPLUS


CN Benzenesulfonamide, 2,3-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 585570-61-2 CAPLUS

CN Benzenesulfonamide, 3,5-dichloro-2-methoxy-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 585570-62-3 CAPLUS

CN Benzenesulfonamide, 4-bromo-2-ethyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)


10/583,590



● HCl


RN 585570-63-4 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 585570-64-5 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 585570-65-6 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)




10/583,590




● HCl

RN 585570-66-7 CAPLUS  
CN Benzenesulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 585570-67-8 CAPLUS  
CN Benzenesulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 585570-68-9 CAPLUS  
CN Benzenesulfonamide, N-(9-bromo-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 585570-69-0 CAPLUS  
CN Benzenesulfonamide, 4-bromo-N-(6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethoxy)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 585570-70-3 CAPLUS  
CN Benzenesulfonamide, 3,5-dichloro-2-methoxy-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 585570-83-8 CAPLUS  
CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(trifluoromethyl)- (CA INDEX NAME)

10/583,590




RN 585570-84-9 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 585570-85-0 CAPLUS

CN Benzenesulfonamide, 3-chloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 585570-87-2 CAPLUS


CN Benzenesulfonamide, 4-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 585570-88-3 CAPLUS


CN Benzenesulfonamide, 2,3-dichloro-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 585570-89-4 CAPLUS

CN Benzenesulfonamide, 3,5-dichloro-2-methoxy-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 585570-90-7 CAPLUS

CN Benzenesulfonamide, 4-bromo-2-ethyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 585570-91-8 CAPLUS


CN Benzenesulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 585570-92-9 CAPLUS


CN Benzenesulfonamide, N-(9-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-3-(trifluoromethyl)- (CA INDEX NAME)

10/583,590




RN 585570-93-0 CAPLUS

CN Benzenesulfonamide, N-(9-bromo-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-  
(CA INDEX NAME)




RN 585570-94-1 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-(6-chloro-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 585570-95-2 CAPLUS

CN Benzenesulfonamide, 3,5-dichloro-2-methoxy-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




IT 585570-71-4P 585570-72-5P 585570-73-6P  
585570-74-7P 585570-75-8P 585570-81-6P  
585570-82-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of 7-arylsulfonamido-2,3,4,5-tetrahydro-1H-benzo[d]azepines  
with 5-HT<sub>6</sub> receptor affinity for the treatment of CNS disorders)


RN 585570-71-4 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
1,2,4,5-tetrahydro-7-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-,  
1,1-dimethylethyl ester (CA INDEX NAME)




RN 585570-72-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
1,2,4,5-tetrahydro-7-[(phenylsulfonyl)amino]-, 1,1-dimethylethyl ester  
(CA INDEX NAME)




RN 585570-73-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid,  
7-[[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-  
, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 585570-74-7 CAPLUS

CN Benzenesulfonamide, 4-bromo-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 585570-75-8 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 585570-81-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[3,5-dichloro-2-methoxyphenyl]sulfonyl]amino]-1,2,4,5-tetrahydro-8-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 585570-82-7 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[[4-bromo-2-(trifluoromethoxy)phenyl]sulfonyl]amino]-6-chloro-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD

L17 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:656734 CAPLUS

DOCUMENT NUMBER: 139:197389

TITLE: Preparation of benzenesulfonamides as antipsychotic agents

INVENTOR(S): Cooper, David Gwyn; Forbes, Ian Thomson; Gribble, Andrew Derrick; Lightfoot, Andrew P.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:




| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| WO 2003068732   | A2   | 20030821 | WO 2003-EP1544  | 20030213   |
| WO 2003068732   | A3   | 20040408 |                 |            |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |            |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |            |
| AU 2003218660   | A1   | 20030904 | AU 2003-218660  | 20030213   |
| EP 1495004  | A2   | 20050112 | EP 2003-711891  | 20030213   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK   |      |          |                 |            |
| JP 2005517705   | T    | 20050616 | JP 2003-567865  | 20030213   |
| US 20050085461  | A1   | 20050421 | US 2004-504110  | 20040810   |
| PRIORITY APPLN. INFO.:  |      |          |                 |            |
|   |      |          | GB 2002-3435    | A 20020213 |
|   |      |          | GB 2002-4721    | A 20020228 |
|   |      |          | WO 2003-EP1544  | W 20030213 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:197389

GI






AB The title compds. [I; A and B = (CH<sub>2</sub>)<sub>m</sub> and (CH<sub>2</sub>)<sub>n</sub>, resp.; R<sub>1</sub> = H, alkyl; R<sub>2</sub> = H, halo, OH, etc.; R<sub>3</sub> = H, alkyl; R<sub>4</sub> = halo, CF<sub>3</sub>, OCF<sub>3</sub>, alkyl, alkoxy, etc.; R<sub>5</sub>, R<sub>6</sub> = H, halo, OH, CN, etc.; m, n = 1-2] and their pharmaceutically acceptable salts, useful in therapy, in particular as antipsychotic agents, were prepared. Thus, reacting the amine II with 4-n-butylphenylsulfonyl chloride in pyridine followed by treatment of the intermediate with 2M NH<sub>3</sub> in MeOH and H<sub>2</sub>O afforded the title compound III. The exemplified compds. I showed pK<sub>i</sub> values within the range of 7.1-9.4 at the dopamine D<sub>3</sub> receptor, and pK<sub>i</sub> values within the range of 6.0-8.8 at the dopamine D<sub>2</sub> receptor.

IT 583025-17-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of benzenesulfonamides as antipsychotic agents)

RN 583025-17-6 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-  
(CA INDEX NAME)




|    |              |              |              |
|----|--------------|--------------|--------------|
| IT | 583025-18-7P | 583025-19-8P | 583025-20-1P |
|    | 583025-21-2P | 583025-22-3P | 583025-26-7P |
|    | 583025-27-8P | 583025-28-9P | 583025-29-0P |
|    | 583025-30-3P | 583025-31-4P | 583025-32-5P |
|    | 583025-33-6P | 583025-34-7P | 583025-35-8P |
|    | 583025-36-9P | 583025-37-0P | 583025-38-1P |
|    | 583025-39-2P | 583025-40-5P | 583025-41-6P |
|    | 583025-42-7P | 583025-43-8P | 583025-44-9P |
|    | 583025-45-0P | 583025-46-1P | 583025-47-2P |
|    | 583025-48-3P | 583025-49-4P | 583025-50-7P |
|    | 583025-52-9P | 583025-70-1P | 583025-71-2P |
|    | 583025-72-3P | 583025-73-4P | 583025-74-5P |
|    | 583025-75-6P | 583025-76-7P | 583025-77-8P |
|    | 583025-78-9P | 583025-79-0P | 583025-80-3P |
|    | 583025-81-4P | 583025-82-5P | 583025-83-6P |
|    | 583025-84-7P | 583025-85-8P | 583025-86-9P |
|    | 583025-87-0P | 583025-88-1P | 583025-89-2P |
|    | 583025-90-5P | 583025-97-2P | 583026-89-5P |

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzenesulfonamides as antipsychotic agents)


RN 583025-18-7 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-19-8 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-methyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 583025-20-1 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)

10/583,590




● HCl

RN 583025-21-2 CAPLUS  
CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 583025-22-3 CAPLUS  
CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 583025-26-7 CAPLUS  
CN Benzenesulfonamide, 4-propyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-27-8 CAPLUS

CN Benzenesulfonamide, 4-propyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-28-9 CAPLUS

CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-29-0 CAPLUS


CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-30-3 CAPLUS


CN Benzenesulfonamide, 4-(1,1-dimethylpropyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-31-4 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylpropyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-32-5 CAPLUS

CN Benzenesulfonamide, 4-pentyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-33-6 CAPLUS


CN Benzenesulfonamide, 4-pentyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-34-7 CAPLUS


CN Benzenesulfonamide, 4-cyclohexyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-35-8 CAPLUS

CN Benzenesulfonamide, 4-iodo-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-36-9 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 583025-37-0 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)



RN 583025-38-1 CAPLUS


CN Benzenesulfonamide, 4-propoxy-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-39-2 CAPLUS

CN Benzenesulfonamide, 4-propoxy-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-40-5 CAPLUS

CN Benzenesulfonamide, 4-butoxy-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-41-6 CAPLUS


CN Benzenesulfonamide, 4-butoxy-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-42-7 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-(3-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-43-8 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(2,3,4,5-tetrahydro-3-propyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-44-9 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(1-methylethyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583025-45-0 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-ethyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-46-1 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-ethyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




10/583,590




RN 583025-47-2 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-propyl-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-48-3 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-propyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-49-4 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-50-7 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-52-9 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(8-ethoxy-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-70-1 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(8-ethoxy-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-71-2 CAPLUS


CN Benzenesulfonamide, 4-propyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-72-3 CAPLUS


CN Benzenesulfonamide, 4-(1-methylethyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-73-4 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylpropyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-74-5 CAPLUS

CN Benzenesulfonamide, 4-pentyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-75-6 CAPLUS


CN Benzenesulfonamide, 4-cyclohexyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-76-7 CAPLUS


CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)

10/583,590




RN 583025-77-8 CAPLUS

CN Benzenesulfonamide, N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)-4-(trifluoromethoxy)- (CA INDEX NAME)




RN 583025-78-9 CAPLUS

CN Benzenesulfonamide, 4-propoxy-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-79-0 CAPLUS


CN Benzenesulfonamide, 4-butoxy-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-80-3 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 583025-81-4 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-methyl-8-(1-methylethoxy)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583025-82-5 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-83-6 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-methyl-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-84-7 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-8-methoxy-1H-3-benzazepin-7-yl)- (CA INDEX NAME)

10/583,590




RN 583025-85-8 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(1-methylethyl)-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




RN 583025-86-9 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-(8-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-87-0 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-(8-ethyl-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



RN 583025-88-1 CAPLUS


CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-methyl-8-(2-thienyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)

10/583,590




RN 583025-89-2 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-8-(2-thienyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583025-90-5 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[8-(2-furanyl)-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583025-97-2 CAPLUS


CN Benzenesulfonamide, 4-cyclohexyl-N-(2,3,4,5-tetrahydro-8-methoxy-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)



10/583,590

RN 583026-89-5 CAPLUS

CN Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)




IT 583026-01-1P 583026-02-2P 583026-03-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzenesulfonamides as antipsychotic agents)


RN 583026-01-1 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)



RN 583026-02-2 CAPLUS

CN Benzenesulfonamide, 4-butyl-N-methyl-N-[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]- (CA INDEX NAME)




RN 583026-03-3 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[4-butylphenyl)sulfonyl]amino]-1,2,4,5-tetrahydro-8-methoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)




10/583,590



|                      |   |  |
|----------------------|---|--|
| OS.CITING REF COUNT: | 2 | THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)                                     |
| REFERENCE COUNT:     | 5 | THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT |

10/583,590

L20 ANSWER 69 OF 69 REGISTRY COPYRIGHT 2011 ACS on STN  
RN 695815-10-2 REGISTRY  
ED Entered STN: 18 Jun 2004  
CN Benzenesulfonamide, 4-butyl-N-methyl-N-(2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepin-7-yl)- (CA INDEX NAME)  
MF C22 H30 N2 O2 S  
CI COM  
SR CA



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*